Wednesday, February 26, 2003

1:30 p.m.

Federal Trade Commission

601 New Jersey Avenue, N.W.

Washington, D.C.
INDEX

Introductory Remarks:

By Chairman Timothy Muris -- Page 3

By Mr. Hewitt Pate -- Page 11

Keynote Address:

By Mr. Tom Scully -- Page 24

Framing Presentations:

By Dr. Paul Ginsburg -- Page 58

By Dr. Mark Pauly -- Page 78

By Dr. Martin Gaynor -- Page 102
CHAIRMAN MURIS: I wanted to welcome everyone to our new conference center. This is our inaugural event, the first event in this facility, and we're quite excited to be here. When we held a health care workshop with the Antitrust Division last fall, we actually had to have two overflow rooms. And the snow has obviously kept things down a little bit today, but it's certainly nice to have a facility where we can hold conferences, workshops, roundtables.

We do a lot of this at the FTC and we moved our staff into this building toward the end of last year, and as I said, this is the inaugural event. So, I wanted to welcome you to this event, to these hearings on Health Care and Competition Law and Policy, which we're jointly hosting with the Department of Justice.

Over the next seven months, we'll devote 30 days of hearings to a variety of subjects in the health care financing and delivering markets. Consistent with the broad mandate of the Federal Trade Commission, we'll examine these issues through the lens of competition law and policy, encompassing antitrust, consumer protection and competition advocacy.

Today, we're releasing a detailed agenda for
the next month of hearings and an outline for the balance of the hearings. In brief, March will be devoted to hospitals; April to insurers -- I don't know if there's any connection with tax month -- May to quality and consumer information; and June, to physicians and non-price competition. July and September will cover a range of subjects, including pharmaceuticals, long-term care, Medicare, remedies for anti-competitive conduct, and international perspectives on competition law and policy. Each month, we'll hold three to five days of hearings.

In keeping with the basic medical insight that diagnosis must precede treatment, we'll gather the information necessary to understand how the markets for the financing and delivery of health care currently work. We will identify and characterize particular examples of market and regulatory failure and evaluate the costs and benefits of various responses.

Around the FTC, we refer to all these activities as policy research and development. Our goals are information gathering, dialogue and consensus building. When the hearings are over, we will use the information to prepare a comprehensive report. In the interim, we'll post the testimony and documentation on our website within a few weeks of each hearing.

The hearings will provide the most up-to-date
and in-depth information available on the performance of various sectors of health care. The hearings should also help us make our decisions regarding enforcement and non-enforcement more transparent, which will be of considerable benefit to the health care bar.

These hearings are not the first foray of the Federal Trade Commission into health care. In the mid-1970s, when I was an Assistant to the Director of the Planning Office, my first job at the FTC, we established a task force to investigate occupational regulation in several industries, including health care. In the intervening three decades, the antitrust and consumer protection authorities; for antitrust, the FTC and DOJ; and for consumer protection, the FTC, have been a constant presence in the health care marketplace, bringing enforcement actions against hospitals, physicians, trade associations, pharmaceutical companies, promoters of fraudulent cures, and a wide range of other individuals and entities.

These are also not our first meetings about health care and competition law and policy. Last September, we held a two-day workshop on health care in which we examined numerous issues. These hearings are certainly our most ambitious foray on the subject.

Indeed, whether one judges by the number of days, the For The Record, Inc.
Waldorf, Maryland
(301) 870-8025
scope of the subjects covered or the commitment of
resources, these hearings are one of the most ambitious
policy R&D initiatives in the Commission’s history.

I'm particularly pleased that a full seven days
will be devoted to consumer information issues in health
care. In the past, the focus of our consumer protection
initiatives in health care has been fraud and deception,
including the deceptive advertising of diet supplements
and miracle cancer cures. Yet, consumer information
problems in health care are obviously not limited to
fraud and deception. Informational asymmetries in health
care are pervasive, particularly regarding quality. The
hearings will accordingly address the availability of
information regarding the quality of care provided by
hospitals, physicians, nursing homes and other providers
of professional services.

Measuring and disseminating information about
health care quality raises complex issues that we will
explore at length. One of these issues is the historical
opposition of professional organizations to the
advertising of cost and quality information regarding
professional services. The Commission has long advocated
using competition to deliver truthful and accurate
information to consumers, and has consistently supported
the voluntary disclosure of truthful, non-deceptive
information by market participants.

Our position is the same as that of Nobel Laureate George Stigler, who once observed that advertising is an immensely powerful instrument for the elimination of ignorance.

These hearings also will help provide a factual foundation to respond to the Supreme Court's challenge in California Dental. Our enforcement efforts involving advertising in the professions must be based on actual empirical evidence, not on assumptions and presumptions.

Quality is a crucial part of the competitive mix when purchasing health care. Competition law does not hinder the delivery of high quality care. We will always consider arguments that a particular transaction or certain conduct will improve quality. Competition law also does not prevent efforts to disseminate information about what providers perceive to be barriers to enhanced quality.

The favorable advisory opinion earlier this month from the staff of our Bureau of Competition responding to the request of physicians in Dayton to collect and disseminate information regarding fees and quality exemplifies our position in this area.

When the Federal Trade Commission began in 1915, it encompassed both research and enforcement.
These hearings grow from the former, but we hope and expect they will contribute to the latter. In particular, we want to know what we are doing that we should stop and what we are not doing that we should begin. Our goal is to ensure that our enforcement uses the best available economic theory and the best possible understanding of the underlying facts. The hearings present a useful, non-adversarial setting to examine these issues.

There's no question that applying competition and consumer protection law and policy to health care is challenging, particularly when the issue is quality of care. Yet, the market is the engine for ensuring that the one-seventh of our GDP spent on health care results in the efficient delivery of the services Americans desire.

Aggressive competition promotes lower prices, higher quality, greater innovation and enhanced access. More concretely, in health care, competition results in new and improved drugs, cheaper generic drugs, treatments with less pain and fewer side effects, and treatments offered in a manner and location consumers desire.

Antitrust law exists to stop those who would interfere with these outcomes in favor of their own self-interest or their idiosyncratic view of what patients
actually need. Theory and practice confirm that such interference with competition is far more likely to hurt consumers than to help them.

We do not have a preexisting preference for any particular model for the financing and delivery of health care. Such matters are best left to the marketplace. What the Commission does have is a commitment to vigorous competition along both price and non-price parameters.

Let me close by acknowledging that hearings such as these do not take place at all, let alone include the talent we have assembled over the next three days, and are assembling over the next seven months, without an extraordinary degree of hard work and commitment at both the FTC and the Department of Justice.

As Chairman, my job is to pick the right people to make sure the work gets done and done well. Here at the FTC, these talented people include Bill Kovacic, our General Counsel; Susan DeSanti, the Deputy General Counsel for Policy Studies; David Hyman, Special Counsel, currently on loan to the Commission from the University of Maryland School of Law and he has the distinction of having both a JD and an MD; Sarah Mathias from the General Counsel's Office; Nicole Gorham, a paralegal in the General Counsel's Office; and Angela Wilson, an administrative assistant from the Policy Studies Group.
I especially wish to thank my fellow Commissioners for supporting these hearings.

I hope you will find these hearings to be both educational and enjoyable. As Bob Pitofsky, my predecessor, noted in a speech on health care he gave six years ago, in health care, as in no other area, there appears to be a recurring need to return to first principles and to talk about why competition and antitrust enforcement makes sense. These hearings mark our attempt to return to first principles and talk and listen about why competition, antitrust enforcement and consumer protection make sense in health care.

Let me now introduce Hew Pate, my counterpart at the Department of Justice, who will make some opening remarks as well. Hew is the Acting Assistant Attorney General of the Antitrust Division. Prior to his current appointment, Hew served as Deputy Assistant Attorney General in the Division. Before joining the Department, Hew had a very successful career at the law firm of Hunton and Williams as a partner in their antitrust group. He litigated cases relating to the competitive process, including antitrust, patent, trademark, trade secrets, false advertising and business torts.

Hew has also had the wonderful opportunity of clerking for several outstanding jurists, Supreme Court
Justice Kennedy, former Supreme Court Justice Powell, and Judge Harvie Wilkinson of the U.S. Court of Appeals for the Fourth Circuit.

I'm delighted to have the opportunity to work with Hew and his colleagues. One of the great pleasures of working in the government is the opportunity to meet and to work with people as outstanding as Hew, and I'm especially pleased that the FTC and the Division are working together to hold these hearings.

Please welcome my colleague, Hew Pate.

(Applause.)

MR. PATE: Thanks very much, Tim. It's a real pleasure to be able to participate in the first day of these joint hearings on the topic of health care and the role of competition law and policy in the health care arena. The great playwright, Menander, is credited with saying that health and intellect are the two blessings of life. Well, if that's right, I guess this is the place to be. And on the intellect front, we certainly are going to be blessed with a number of speakers that have been assembled through the hard work of our staffs at the FTC and the DOJ.

We have an impressive list of speakers just today, including Thomas Scully who will be joining us. So, I want to be very brief in covering three points.
The first is to underscore the Antitrust Division's past, present and future commitment to vigorous enforcement in the health care arena.

The second is to mention, from the DOJ perspective, some of the highlights among the topics that we will examine this spring during the parts of these hearings that will be hosted at the Great Hall over at Main Justice, primarily dealing with the payer side of the field. And third, I think this is a perfect occasion to mention the great public benefits that I think are produced by having collaborative efforts by two separate competition and consumer-oriented agencies working together on projects of this type.

Turning first to the Division's activity in this field, I don't want to belabor the statistics that all of you are familiar with demonstrating that health care is an extremely important part of the economy, nor that the figures showing that the rise in health care costs is really a critically important public policy issue in the United States today.

Let me simply say together with Tim, that while there are likely to be many factors that have influenced increases in health care costs and likely to be many complexities in terms of dealing with the situation, we share with Tim a faith in open competition in the market...
as a very critical component to containing health care
costs and to providing the best quality of services for
consumers.

At the Division, for our part, we are trying to
back that commitment up through vigorous enforcement of
the antitrust laws. Our lawyers, at different times,
have done that in different shops. We used to have a
Professions and Intellectual Property Section. We have
had, at various times, a health care task force. We now
have, under the leadership of Mark Botti at our
Litigation I shop, a strong group of health care lawyers
supported by economists from our economic analysis group,
and we're very active in this field, not only in terms of
litigation, but in providing guidance jointly with the
FTC, as was the case with the policy statements on health
care adopted in 1993 and then revised in 1996.

In the past decade, the Division has brought
nearly 20 cases and we've issued over 55 business review
letters in this field. Just in the second half of 2002,
I might mention four major health care initiatives that
were brought to fruition, our Mountain Health Physicians
Decree, which was a case involving a joint fee schedule
adopted by a group of physicians in North Carolina,
where, in an unusual decree, the Division obtained the
dissolution, the disbandment, of a provider organization
that was engaged in anti-competitive activity. Recently, we issued a business review letter similar to Tim's in the Dayton case, our Washington State business review letter, trying to outline the situations in which it is legitimate for providers to share information in a way that can provide pro-competitive benefits without running afoul of the antitrust laws.

With respect to litigated cases, we completed the trial late last year in our Dentsply case, which was a case involving distribution in the artificial tooth industry, a trial that was headed up by Bill Berlin, who is one of the people here today and is working on these hearings, on our side. And then finally I would mention our Federation of Physicians and Dentists case, also from late last year, where we obtained a stringent decree prohibiting collusive activity, which would have forced health plans to pay increased fees.

On the current investigative efforts side, while, of course, I can't go into details of cases that are open, I might just point out the degree to which our efforts are focusing on the conduct of health plans. We're looking right now into two separate matters that focus on the manner in which health plans market and price their products, both to employers and to other groups. One of these focuses on punitive collective

For The Record, Inc.  
Waldorf, Maryland  
(301)870-8025
action by the plans and another focuses on potentially questionable unilateral conduct. We have an active inquiry into a national joint venture among plans that requires us to consider the potential benefits of coordination among health plans in different markets in contracting for national and regional accounts.

We're examining, likewise, the conduct of plans vis-a-vis providers. We have open inquiries into a joint venture among plans and contracting with provider networks, open matters with respect to the imposition of most-favored nation pricing by another plan, and likewise, an allegation that groups of plans have colluded in the setting of provider fees. As to that latter matter, we're currently exploring whether a Grand Jury should be convened in connection with the facts that are uncovered there.

The competitive concern in all but one of these matters focuses on whether payer conduct has reduced the quality or raised the price of plans to their customers. The remaining matter focuses on allegations of collective monopsonization which is a topic that the Division is continuing to study in response to allegations by providers, including allegations contained in the recently released study from the American Medical Association.
By no means do I aim to suggest that our work is confined to the health plan area. We certainly will be active on any appropriate front where we see the need for enforcement. We continue to examine a number of allegations of physician collective bargaining that have exceeded appropriate bounds. We're also taking a close look at issues of integration and competitive effects in regard to a consummated hospital joint operating agreement, as well as a network of hospitals engaged in joint contracting. We, likewise, have two active matters involving medical equipment and products.

So, the point I want to make is simply this, that the Division has a very strong core of attorneys and economists responding to a variety of Congressional, citizen and industry concerns, and that is going to continue to be the case.

With respect to previewing the role of the DOJ in these hearings, we are devoting substantial resources to the hearings and it is really a highlight of my work at the Division as Acting AAG to be able to participate with Tim, who has such a long history of leadership in the application of competition law and consumer protection law in the health care field.

We're going to be actively involved in all of the antitrust sections of the hearings, while, of course,
the FTC will take more of a single role with respect to consumer protection, just as we would take a more exclusive lead on any examination of criminal enforcement issues. But these are truly joint sessions by the two agencies, which you can see right down to the detail of the name tags that all of you have been provided with, the seals of both agencies together.

As to what we're going to be doing in our sessions at the Great Hall, unless these hearings reveal something different, we think our activities during the hearings will confirm as our key, or a key enforcement priority, evaluation of health insurer activity.

Let me just mention a couple of issues that we intend to highlight. First, health insurance monopoly. We were told at the September workshop that one of the key trends shaping health care markets today is continuing consolidation, including consolidation among health plans. One panelist indicated that more than 350 mergers and acquisitions took place over the five-year period between 1995 and 2000. Increasingly, consolidation has been across geographic markets as merging parties have been national firms and regional Blues.

These hearings will explore whether consolidation in this sector is likely to give rise to
market power. We will encourage our diverse panelists to discuss the various competitive effects theories that might predict higher prices to consumers, or a reduction in quality following a merger, and we expect that discussion to range across issues of unilateral effects, coordinated effects and auction theories, as well as devoting substantial time to whether there is a potential for competitive entry in this area that will constrain potential injury to competition.

On the health insurance monopsony side, we're going to be looking to gain further insight regarding the conditions under which plans might obtain and exercise monopsony power against providers. Monopsony, obviously, is the term used to describe market power being exercised by buyers over sellers. And in the health insurance industry, payers are both sellers of insurance to consumers and buyers, for example, of hospital and physician services. And many providers accuse insurance companies of forcing them to accept unreasonably low rates and unattractive contract terms in ways that they say impact quality of care and other issues for consumers.

In response, payers cite substantial competition among health insurers seeking strong provider panels and they cite a consumer backlash against managed

For The Record, Inc.
Waldorf, Maryland
(301)870-8025
care. Payers say that providers thus have more leverage because insurance companies must now have networks with large numbers of physicians or specific physicians in order to respond to consumer demands. We expect to have a robust debate on this issue during these hearings, to put it mildly, and we look forward to it.

Let me just close with a couple of comments on the value of DOJ/FTC collaboration. This is only the second time that the Antitrust Division and the FTC have jointly hosted and sponsored a series of hearings. Tim Muris deserves great credit for promoting this concept, first in the intellectual property hearings that we concluded last year and on which our staffs are now working toward completion of a joint report, and it's not surprising, given Tim's background in the health care field, that this would be the subject for the next set of joint hearings in the area.

Tim and I certainly view the work of the two agencies as complementary and we expect to benefit from the hard work of our staffs in assembling these programs, working together.

For my part, let me just thank some of the folks who have been involved on the DOJ side. Debbie Majoras, who's the Principal Deputy here, has been personally involved in trying to drive these hearings
forward, which I greatly appreciate, given the wide array of enforcement work that she's got to do right now during the transitional period we are in at the Division. Likewise, Special Counsel Leslie Overton has, along with Bill Berlin, a great deal of day-to-day organizational responsibility. I hope that those of you with an interest in these hearings and their success will make yourselves known to Bill and to Leslie and feel free to pass on to them your input for how we can make the range of sessions more productive.

From a broader perspective, I think these hearings really exemplify the benefits of having two separate agencies working on competition related issues. Perhaps the benefits are unintended. There's certainly a lot of folks who point out that nobody would have designed a system with two separate Federal agencies with so much overlapping responsibility. I think maybe this is a little simplistic and it ignores the fact that some of life's most effective arrangements really are the product less of an elegant design than of historic accident and a lot of hard work in the intervening years. That's the case with the Antitrust Division and FTC. And we hope that our overlapping and, hopefully, complementary efforts can provide real benefits to the cause of promoting competition for the benefit of
consumers.

The agencies differ, of course, in many ways. The Division is charged with criminal enforcement, for example, which is not part of the FTC's authority. Likewise, the FTC has important consumer protection functions that we don't share at DOJ. It might be fairly said that at the Division, not surprisingly since we're a component of the Justice Department, we see ourselves more primarily as law enforcement. Likewise, I think some of my colleagues at the FTC take a great deal of pride in the FTC's policy leadership and ability to do empirical research.

None of this is to say that the FTC isn't a great enforcement agency or that we're not interested in policy, but my point is that there are differences of approach at the agencies and I think the public can benefit from this. This happens in our day-to-day operations, whether it be a criminal case referral from the FTC to the Division, or to the benefits that our lawyers derive from relying on the research and policy leadership and empirical work that the FTC is so well suited to and was created to do.

It even happens in areas of overlapping interest and through initiatives that are sometimes spurred by a little bit of friendly rivalry, and that's
not a bad thing so long as we avoid inefficiency and duplication.

Obviously, I think these joint hearings are really an example of FTC/DOJ collaboration at its best, and I'm very happy to have had an opportunity to participate in opening the hearings and look forward to seeing many of you as the hearings go forward over the next months.

Thank you very much.

(Applause.)

CHAIRMAN MURIS: Thank you very much, Hew.

It's now with great pleasure that I introduce my friend, Tom Scully, who will deliver our keynote address. Tom has had a very impressive career in both the public and private sectors. Currently, as you know, he's the Administrator of the Centers for Medicare and Medicaid Services at the Department of Health and Human Services. I've only now gotten used to calling it CMS. It's responsible for the management of Medicare, Medicaid, the State Children's Health Insurance Program and other national health care initiatives. Hew was talking about monopsony. Well, Tom may be a monopsonist.

(Laughter.)

CHAIRMAN MURIS: CMS is directly responsible for one out of every three dollars spent on health care.
in the United States. CMS insures over 70 million
beneficiaries, including the elderly, disabled and some
of the lowest income individuals in the country.

Before joining CMS, Tom served in numerous
positions. He worked at the White House as Deputy
Assistant to the President and Counselor to the Director
of the Office of Management and Budget, and as the
Associate Director of OMB for Human Resources Veterans in
Labor or HRVL, as it used to be called, from 1989 through
1992. Tom and I are both OMB alums and have often
discussed health care issues together. I'd like to say
that all the discussions were about lofty issues about
patient quality and the direction of health care, but
that wouldn't be completely true.

One of the first discussions we had was in a
meeting when I was out of the government, but I was
brought in to chat with Tom about creep and whether there
was a distinction between real creep and coding creep.
This is in the reimbursement formula for hospitals. We
also spent time discussing arcane issues such as the MEI
and the new-then Physician Reimbursement System, which
continues to this day to be a prominent part of Tom's
life.

But I have seen, firsthand, his dedication to
improving the health care system as well as to mastering
these arcane details. In the private sector, he was President and CEO of the Federation of American Hospitals and earlier a Partner in the D.C. firm of Patton Boggs, L.L.P. So, I'm honored that Tom has come today, and please welcome my friend and colleague, Tom Scully.

MR. SCULLY: Thank you. I'm honored to be in the same room with Tim, who's probably the smartest guy I know in Washington. So, he's given me a lot of great advice over the years. I don't know Hew as well yet, but hopefully with more interaction between CMS and Justice on antitrust issues, that should make the crowd happy to start.

(Laughter.)

MR. SCULLY: We'll get to know each other a lot better. But we are OMB alums. There is kind of a little OMB mafia that's left over from all the years of people at OMB, and Tim's been very helpful to me in a lot of ways over the years. But he's a much smarter guy than I am on all these issues. But we've spent a lot of time in the last couple years working on this and I hope to work together a lot more.

I was -- I told Tim briefly -- a really bad antitrust lawyer. I have to switch careers every couple years. When you're not very good at anything, you got to -- in fact, my law review article in antitrust 20 years
ago, I think my mom read it. I'm not sure anybody else ever read it. It's probably been buried in those law
libraries. So, I can't claim to know anywhere near as much as either of these guys, but I do really think as somebody who's a regulator and probably the biggest price fixer left outside of what's left of Eastern Europe, I really have always believed that if you're a market-oriented, conservative economic type person, the most important regulation on the market is antitrust regulation and balancing markets to make sure that no particular piece of the market gets out of hand.

I'm a big regulator, we regulate an awful lot of -- and I'll get into that in a few minutes -- we fix a lot of prices for a lot of people. I hate fixing prices, but as long as I am where I am, I try to be the best price fixer I can be. But the nature of the beast makes the market a little strange, which I'll get into. But if you really want to make sure that the economy works and you're a Republican and you're a moderate conservative and you actually believe in balancing the markets and making sure that nobody gets excessive market power is pretty critical, and I think that's why, as important as anything I do in Medicare or Medicaid, having Justice and the FTC make sure that market power doesn't get out of hand for anybody is really critical. And I'll talk about
that primarily for the next few minutes.

Before I circle back to antitrust, let me talk about health care markets. First of all, I think when you talk about health care markets and health care, it's kind of an oxymoron. The fact is, the health care market, whatever there is in health care, is extremely muted and extremely screwed up and it's largely because of my agency. For those of you who don't follow CMS, which used to be called HCFA, we changed the name because it was so well loved. I always say it's kind of like when Enron comes out of bankruptcy, they'll probably change their name. So, HCFA -- Secretary Thompson and I decided to confuse everybody. We changed the name to CMS for a couple of years so people wouldn't realize we're actually HCFA. So far, it's worked reasonably well.

(Laughter.)

MR. SCULLY: But there were a lot of reasons. Because we're so big and we are so extensively involved in the health care field, both in Medicare and Medicaid, that you obviously, when you're spending that kind of money and you're -- our budget, if you count both halves of Medicaid this year, is $570 billion is the projection for 2004 that just came out. $570 billion. It's $450 billion just directly for us and another $120 billion that the states will spend through us on Medicaid. So,
it's a lot of money and it affects every sector of the
health care field.

Generally, one of the things I've found -- I've
never been really good at making people happy, as Tim
knows. That's your training at OMB. You train for years
how to make people miserable and we both succeeded in
some cases. But when you're fixing rates for hospitals
and docs and other things, they're never really quite
happy. And when you have large, incredibly complicated
formulas, you make mistakes that don't make people happy.

But the bottom line is there really isn't much
of a health care market and the reason is that when you
look at a hospital, for instance, 57 percent -- Mindy is
here somewhere. I was reading the AHA's comments
yesterday. Fifty-seven percent of the average hospital's
revenues come from Medicare and Medicaid. So, if you're
sitting there as a hospital administrator and you're
looking at 57 percent of your revenues coming from
Medicare and Medicaid, probably 6 or 7 percent are
indigent care, the market forces you have to deal with in
the private sector on insurance are pretty muted. It's
not much of a market. Let's kind of kick the ball and
drag the government along when you're setting prices for
everything else.

In the nursing home field, 82 percent of the

For The Record, Inc.
Waldorf, Maryland
(301) 870-8025
nursing homes in this country are now filled with either Medicare or Medicaid patients. That doesn't leave a whole lot left for the private sector to change the nursing homes. It depends on the physician, but many physicians and many physician specialties treat -- 70, 80 percent of their patients are Medicare patients. So, that doesn't leave a whole lot of flexibility to negotiate with the private sector.

So, you inherently have a pretty limited market force in the health care market as it is. And what's the reason for that? I only have 40 million seniors in the Medicare program, but obviously seniors consume the most health care. And even though they're only one out of seven Americans, seniors and with Medicaid together generally consume about half the health care in the United States. So, when the government, either Federal or State, is fixing prices, the rest of the market's flexibility to respond to that is kind of muted.

So, while I'm a big advocate of instilling and restoring competition whenever possible in the health care market, by its nature, it's always going to be a little bit limited and it's never going to be particularly responsive, and some people don't believe there's a role for the markets in health care. I don't happen to be one of them, and I, obviously, don't think
Tim or, I guess, Hew are either. But you have to look at the fact that when you're talking about health care, you're looking at a market that is not structured like markets for anything else in our society and probably shouldn't be.

But there's still a place, I think, for it to work. I think health care, for me -- and for those of you -- I assume a lot of you are health care people. A lot of my friends on the Democratic side think we need single payer health care. Well, we already have single payer health care. If you're over 65 years old, we have a single payer. Medicare is a single payer, national health system and it's a wonderful system. There's nobody over the age of 65 that's uninsured. But it's an unbelievably archaic, crazy, nutty system where we do a lot of -- we essentially fix prices for everything.

Just to give you the most recent example, for the doctors -- a formula I was involved in in 1989 -- the Physician Pay Reform. We came up with a better way to fix prices than the old way to fix prices in 1989. I don't like fixing prices, but it was better than the old way. It was broken and we made a mistake. So, last year, every doctor in the country got a negative 5.4 percent reduction in their base payment in health care because we screwed up the formula. We made an accident.
Congress had to come back and fix it. That's a pretty crazy way to pay physicians.

On top of that, this year, until last week when Congress finally fixed it, we were going to give them another negative 4.4 percent reduction in their payments. So, when you're getting these big national price-fixing schemes, not only are they not necessarily working, they're not flexible and they don't reward people for quality, but they also do stupid things like have, you know, cumulative 11 percent payment reductions over two years for docs, which had it not been fixed last week, you would have seen every one of your grandmothers going to a doctor's office in the next few months and them saying, sorry, we don't take Medicare patients anymore, which would not have been a pleasant thing.

So, there are wonderful things about Medicare, but I don't know of anybody, Democrat or Republican, that would take $270 billion, which is the Medicare budget this year, and create what we have. It's a 1965 broken system and we're going to do a lot of things to try to fix it. But it is what it is. It dominates a lot of health care.

And even if you're the private insurance market, you find that Medicare rates are frequently piggybacked on even if -- if you don't think Medicare
affects everything, I can tell you that I was on the board of Oxford Health Plans, the biggest HMO in New York for eight years, and Oxford's rates for physicians were all piggybacked off Medicare rates. So, even in the private sector, the government price fixing kind of trickles down in everything and has a really negative impact on the market.

Under 65, we have an incredibly dynamic health care market. You can buy anything you want. High deductible, low deductibles, PPOs, HMOs, fee for service, anything you want. But we also have a cherry picking market where we have lots of people, 40 million people uninsured. So, we have a wonderful single payer broken model that covers everybody over 65 and an incredibly capitalistic dynamic market that cherry picks everybody and leaves an awful lot of people uninsured under 65.

The market under 65 works reasonably well, but it's dragged down a lot by the market over 65 and it's incredibly inequitable and it leaves an awful lot of people uncovered, which is obviously another problem that we hope we're going to work on.

But it is really the one size fits all price fixing that really, in my opinion, screws up the system and makes the market in health care so difficult to either monitor, follow or really understand what's
happening.

So, it's easy to say the system is broken, which I think everybody's been saying in health care for 25 years. I guess the question is, then, which Paul may answer -- in fact, I should note here that you have probably two of the only -- health care is not a bastion for market-oriented people. In fact, if you had a health care market conference, the only two guys I know that would probably show up are Paul Ginsburg and Mark Pauly. That's probably unfair. But there aren't a whole lot of -- it's not a place where you see a lot of big market thinkers in health care and you, obviously, have two of the best ones here today.

But what do you do to try to fix it? Congress has been struggling with the Medicare reform and we're going to struggle again for years. We've been struggling with Medicaid reform. Fundamentally, we're probably not going to fix the system overnight. I've been working on health care issues since I quit being an antitrust lawyer actually, about 20-some years. And one thing I can say is, very little has changed in health care. We talk about big legislative changes all the time and we're hoping to pass one this year. But the reality is, very little changes.

If you look at the fundamental structure of
Medicare and Medicaid, they're virtually the same today as they were in 1980. I hope we get some things fixed, but I try to be realistic, and I think the odds are not great that we're going to get overwhelming changes.

So, if you're in my position or you're in Tommy Thompson's position, my boss who runs HHS, what do you do? My view is, you try to find ways you can to instill market awareness into the system to make it more reactive and make it work better.

And one of the things we've really focused on, I've focused on, is quality. It drives me crazy that somebody flew into Washington, D.C. for this conference today. If you landed at the airport, you can find the best cab company, the best car and driver, the best hotel, and the best hot pizza, but if you had a heart attack, you'd have no clue where to go to get a bypass because nobody would know who has the best heart bypass program in Washington, nobody would know who does the best hip replacements. There's no information out there.

So, if you're trying to instill any market awareness, no market works if the consumer has no information. Now, obviously, you would hope that the consumer has some skin in the game and is actually paying something, which in health care frequently we are, and in most cases, seniors don't pay anything. They generally
are completely insured with first dollar coverage, once
you get through Medicare and Medigap. So, their own
market awareness is pretty muted, but at least you want
them to know where do you go for the best hospital care,
where can you find the best nursing home, where do you
get the best home health agency. There's virtually
nothing out there.

We pay every hospital in Washington, D.C. the
exact same amount, varying depending on whether they're a
teaching hospital. But if you ignore those details, they
all get paid the same amount for a hip replacement and
the same amount for a heart bypass, if you're the best
hospital or the worst hospital. There's nobody in this
room, including the health reporters, that could tell you
which the best one is. My father had a heart attack
three years ago in Maryland and I had a half an hour to
find the hospital. I ran the second-biggest hospital
association in the country then and I had a half an hour
to tell the guys where to bring him for an emergency
bypass. I had to call 10 doctors in Maryland. I had no
idea. That's insanity. There's no place else in our
society where there's that total lack of information.

So, one of the things that Secretary Thompson
and I pushed very hard, and it's probably just pushing at
the edge of the system, but we think it's pretty
important, is to get information out there.

Twenty-five years ago or 20 years ago for those of you who do follow health care, Bill Roper is an old friend of mine and was then the HCFA administrator, back when we called it HCFA. He put out mortality data, which he thought was a good idea to start comparing hospitals, and he got creamed. The myth in the health care field since then has been you can't possibly put out quality information, providers will kill you and it can't be done. And when I came into the job, that's what everybody said, you're nuts to try to do that, it can't be done.

Well, to be honest with you, I picked on the weakest people on purpose in the health care system to begin with, the nursing homes, because, number one, they had a bad public image, which they understood; they had a miserable relationship with their unions and the consumer groups; they wanted a lot more money from Washington. And so, I got the nursing homes together with Secretary Thompson's help and said, look, if you want more money from Washington, you better start talking about quality and measuring quality because the consumer groups hate you and think you're providing bad quality. You're getting no sympathy in state capitols and none in Washington. So, if you want us to work with you, start
measuring quality and put out quality outcomes.

We got all the major unions and all the major -- AARP and all the other health care groups that are consumer groups, who generally never talk to each other and didn't talk to the nursing homes, and the nursing homes in a room about a year and a half ago and we started -- people thought we were crazy. We did a six-day demo where we published outcomes -- you know, it's not perfect -- on major nursing home outcomes in major newspapers in those states and everybody said, you're crazy, you're going to get killed, and I did get beat up a little bit.

Last October, we published full page ads in every newspaper in the country in every major market comparing every nursing home in the country and I didn't hear a peep. Unbelievably popular. The nursing homes are happy, the consumer groups are happy, the unions are happy, and it's going extremely well, and they're fair, reasonable outcomes data.

Does every senior when they open the Washington Post and see that understand it? No, they don't understand it. But the families understand it. The patients understand it a little bit. I can guarantee you the nurses understand it and the boards of the nursing homes read it and they change. It has a big impact when
you start putting patient quality information out there because the boards of the nursing homes start asking their employees, how come we have the number one number of bed sores in the community.

And my view is, that may seem irrelevant to markets, but I think eventually when people start seeing this and they see we've got 43 nursing homes in Washington, D.C., why are we paying them all the same amount when one's doing a great job and one's doing a terrible job. Nobody ever asks those kind of questions in health care. They certainly ask that kind of question if the government goes out and bought a fleet of cars. They'd certainly figure out which Ford or which GM or which Chrysler cost them more money or performed the best. But they never think about it when they start to talk about health care.

So, my own view is once you start putting information out there and comparing quality, people are going to say, why are we paying every hospital in Washington, D.C. the same amount for a heart bypass when one's doing a great job with taxpayer money and one's doing a terrible job, and I believe that's going to inject a little bit of market -- at least a teeny bit, of market pressure into the health care field.

We're doing a demonstration in eight states
starting next month with home health care. We have 22,000 home health agencies around the country. We have extremely thorough data on every home health patient that goes in every home health agency in this country, whether it's Medicare, Medicaid or the private sector. We have it in our computer systems. We've never given it to anybody.

In eight states, as of next month, we're going to have full page ads in those eight states talking about relative home health care. So, if your grandmother or your parent gets out of the hospital and is trying to figure out which home health agency to go to, Medicare pays every dollar, no deductibles. I think it would be nice if one of them started wondering which of those places does the best quality and which one is likely to take the best care of them. There's no source of information on that now.

As of next month, you'll have it in eight states, and as of next October, you'll have it in 50 states -- again, as soon as my budget -- somebody will eventually figure out to cut off my budget so I can't pay for anything probably -- with full-page ads in the newspaper. And eventually, and I know they're nervous about it, we have tons of data on nursing homes and we have tons of data -- in nursing homes we have something
we can use the MDS System, which we have extensive data
on every nursing home patient and we have exactly the
same thing in home health. We don't have that in
hospitals. And, obviously, the biggest institutional
provider that's the most sensitive is hospitals. In all
fairness to the hospitals, we don't have a standardized
measuring system for hospitals. The VHA and the
Federation which I used to run and the teaching hospitals
have all been very good about working with us because we
have to build a base to get that information out there.

But eventually, the real final thing that
consumers are going to want that's going to drive change
is hospital data, and then eventually, which is even
tougher because it's such a balkanized field, is
physician data. But we really believe that the thing
that we can do as regulators to change the system is to
start putting information out there and having people
start asking the same questions about the health care
system that they ask about everything else in their
lives.

You know, we're 13 percent of the economy.
Medicare is the only part that is 100 percent government-
driven, has no competition, no information, and that's
bad for everybody. So, I think our view is for consumers
to really look at changing the system, we have to start
questioning government price fixing. Obviously, as you
can tell, philosophically, this administration doesn't --
you know, we love Medicare, it's a wonderful system, it's
great for seniors and they love it. We don't think
setting prices for every hospital and every doctor is a
good idea. Hypothetically, we'd like to give seniors
what every Federal employee has, which is the choice of a
fully-funded, extremely thorough, well-crafted Federal
employee health benefits type program where they can pick
PPOs and private fee for service.

We're going to keep around Medicare fee for
service forever. It's a great program. Seniors are
comfortable with it. The last thing we want to do is
scare anybody. But most of the people in this room have
grown up with PPOs, have grown up buying Blue Cross
plans, have gotten used to working with CIGNA, want
choices. Maybe you want to be in the old government
programs.

But you want the choices to go out and get
flexible benefits, and this kind of one size fits all
government price fixing is -- it's a wonderful program.
It's worked extremely well for 30 years, but nobody in
their right mind, even the most liberal Democrat I know,
would ever recreate what we've got, because it's crazy
and it doesn't make any sense. That price fixing doesn't
make any sense and lack of consumer information doesn't make any sense.

So, let me just jump into one other thing we've been trying to do to put a little bit of market incentive and then I'll circle back. They may not actually tie together, but what the hell.

(Laughter.)

MR. SCULLY: To antitrust, why I think it's important is when I came into this job, I also thought it was astounding that the hospitals and the nursing homes would all come running to my office and say, we need more money. I used to do the same thing. I was a hospital lobbyist for seven years, and it's like Pavlov's Bell, whether you need it or not, you come in and say, we need more money.

Well, there's absolutely no substantive data from the government to figure out, outside occasionally from Paul and MedPAC, what people really -- what their margins really are. And I know for one, I used to represent the for-profit hospitals and I would run up to the Hill and say, we're doing terrible, I need a lot more money. And then I'd hop on a shuttle and go to New York and say, we're doing great, buy our bonds and securities, and nobody ever tied those two together.

(Laughter.)
MR. SCULLY: So, now that I'm a regulator, I think it's insane. I think if you want to -- and the SEC is starting to catch on to this, too. If you want to go up to the Hill and tell people you're doing terrible, you shouldn't be able to go to Wall Street and tell them something different. And I think the flow of information between Wall Street and Washington is getting better, but it's still a little bit muted.

So, when I came in, I hired two Wall Street analysts, which was a little bit unusual, and I don't know if anybody reads this, but people in New York actually read it, and the goal was to educate people that when the hospitals come in and need money -- and I think they got creamed in 1997 and I lobbied for more money for them in '98 and '99 because they deserved it. But when the hospitals and nursing homes come in and say we need more money, I'd like somebody to look at the bond ratings and their stock prices and the returns on equity and what -- to actually have a measure of do they need more money or not. Are they just, you know, crying wolf or do they actually need money?

The first result of that last year, the first report we put out was one on nursing homes, and we massively overpay nursing homes in Medicare, huge margins, 25, 30 percent, which MedPAC just came out and
reported. But that's only about 12 percent of their business is Medicare. But overall, we massively underpay them. Not us. The states set the rate in Medicaid. They chronically underpay them and it's going to get worse in every session.

So, when you look at the net Medicaid margins, they're pretty low, and a number -- some of them, they brought themselves and I won't torture you with the reimbursement of nursing homes, but when my analyst went through and wrote their first report, it turned out that nursing home margins were minimal. We weren't drawing much more capital into the market, things weren't going very well. And I can tell you that OMB in the White House last year, we had the option of putting a billion dollars a year, which out of a $12 billion base for nursing homes is not small, back into the nursing homes or not. And because of that report last year, we put a billion dollars, called RUGS payments, back into the nursing homes without any great debate.

It was an administrative change we could make in the Medicare program because we thought the nursing homes needed money. It was done 100 percent on the merits. So, you can imagine, OMB doesn't put a billion dollars in anything unless they think it's a pretty dire system.
We just decided, again, to put another billion back in for the next two years for nursing homes because we believe, on the merits, looking at the economic information, that their margins are not great.

With the hospitals, which I'm sure many of you don't like to hear, I've been saying that I think hospitals are about where they should be. We shouldn't cut them, we probably shouldn't add much back. Now, there's a lot of definitions about leaving them where they are. But I really believe that in Washington too often those kind of decisions aren't made based on economic reality, they're based on who hires the best lobbyist and I don't think that makes a lot of sense. So, I'm a real believer that when you run a big agency like we do that dominates that big a part of the health care sector, then we ought to be looking at bond ratings, equity ratings, returns, you know, what the access to capital is, and that hasn't been done before.

I think tying together with the private equity markets and the private debt markets look at with what decision makers make in Washington, because we basically are giant government contractors. CMS is the biggest government contractor in the government. Social Security is slightly bigger than we are, but they pay money to individuals. I pay out $570 billion a year largely to
institutions and that's almost twice what the Pentagon is
paying out right now. So, we are a giant government
contract. People don't think of us that way, but that's
really what we are.

So, I really think that when we look at it, we
need to think just as regulators, that HHS, CMS, me,
needs to be a more reliable, predictable payer, more
reliable, predictable government contractor, be much more
sensitized to what's going on in the private market, to
think about our impact on the private markets, which we
rarely do.

I'll give you one other example which came up
yesterday in a meeting with Mindy at HHS. We pay for
exactly the same procedure in ambulatory surgery centers,
in hospital outpatient clinics, and at a doctor's office.
But yet when I sit down with my staff, we pay totally
different amounts for say a colonoscopy. You can get a
colonoscopy in any one of the three settings. You
probably don't want one, but you can get one.

(Laughter.)

MR. SCULLY: So, if you want to get a
colonoscopy in any of those three settings, you'd get
paid a totally different amount. And they're all set by
-- I've got a third of my staff in hospitals, a third in
the outpatient side and some guy setting ASC rates and
they never talk to each other. And when you find out that you set those different rates, you get enormous changes in behavior. If the ASC rate is off, all of a sudden you start seeing ASCs pop up all over the place to do colonoscopies or to do outpatient surgery. If the doctors get paid a little less, they're more likely to move their practice into their doctor's offices. If the hospitals get paid a little more, they're going to have more outpatient centers.

But people in the government don't look at it that way, and it's not because they're not trying to think well-intentioned, but I can tell you when I drive around the country and see where ASCs are popping up, I can tell who we're overpaying. You go back and check the rates and, hmm, there you go. That's why we've got more ambulatory surgery centers for orthopedics.

But we need to start thinking more about the impact we have on the market because we're such a big player. So, hopefully, we'll make HHS a little more responsible to the market and a little more of a better player. I also think that if you look back at health care in the last 20 years, people buy health care stocks and health care bonds because they expect health care to be a boring government contract. In the last 20 years, it's been anything but. The nursing home industry has
been a big roller coaster. Some of it's self-imposed, but usually driven by stupid government policies, where they've had huge margins and then the government whacks them and they have huge cuts. Big margins, big cuts.

Same thing with the home health business. The home health business, just to tell you how bad it is, in home health, the Medicare program in 1992 spent $3 billion; in 1997, it spent $18 billion; and in 2000, it spent $10 billion. There's nothing like that in the history of the government, where you went from $3 billion to $18 billion and back to $10 billion. You can imagine if you're in the home health business, it's like being on a big yo-yo. There are a lot of big yo-yos that got in the home health business there for a while, but the fact is you're --

(Laughter.)

MR. SCULLY: We're back to where we probably should have been all along without the big bulge. But the fact is, if you're in the government, I think the goal should be to understand better about what our impact is and to become a more predictable, better partner in the market because if the market is going to work better, the government shouldn't be distorting the outcomes as much as we are.

We'd obviously like to get more market based,
non-price fixed payment into that market, and I think in a good market, the government will have a lot lesser role. But in the long run, that might change. But in the short run, we're still going to be, by far, the biggest player in the market, and to the extent that we're screwing up the dynamics of the market, that makes everybody's life more difficult.

Now, trying to tie this back into the FTC and Justice and what happens with antitrust, I've always believed that the most important player in the market is the FTC and Justice in balancing out antitrust because health care is a local business. You can look at big chains, you can look across the country. What you have across the country is a market power that's making a difference. What you have in Washington, D.C. or Baltimore or Richmond or Paducah, Kentucky or -- what was the other one -- Poplar Bluffs, Missouri, that's what counts, is how much market power you have in those places.

And I've always believed, and I've been in the health care business for a long time, if you go to a town that has a healthy health care market, the doctors hate the hospitals, the hospitals hate the health plans and the health plans hate the doctors. That's a happy little triangle. Those are the three big players and that's the
way it should be. The hospitals should be a little bit unhappy, the health plans should be a little unhappy, the doctors should be a little unhappy, and if you have that kind of tension and balance, you usually have a reasonably efficient, well-run health care system. Over the last 10 years, that’s just a fact.

I mean, I wouldn’t pick Washington, D.C., but I was in Milwaukee last week and I can tell you Milwaukee has probably eight or nine relatively functional health care centers. They probably have too many hospitals, but they’re broken up into four big chains that have consolidated, but they haven’t consolidated too much. And they have a pretty active, reasonably well organized physician community. It’s been a little out-of-whack in the last 10 years, but right now, it’s kind of in balance, and you can look at almost any community in the country and see where that balance is between the big players and tell whether you’ve got a problem on your hands or not.

And I think in the last 10 years, with all due respect, and Tim and I have talked about this a lot, the lack of the government’s focus on keeping those tensions in balance has been a big problem. I think it’s one of the reasons we’ve had health care prices going up.

Because when the government -- you know, I’m not a big
regulator, I don’t believe in over-regulating. But I believe if you’re conservative, the right regulation is keeping the market in balance, not diving into the market and micro-managing, and I would much rather have these guys manage the market and oversee it to make sure it’s in balance from 30,000 feet than to have my people get in and micro-manage every little detail with every hospital and every nursing home. And I think in the long run that’s the best thing for the health care system.

So, what I think are the problems here, I’ll give you a couple of examples which will probably irritate a whole bunch of people in a couple of cities, but that’s my specialty. So, I’ll go for that.

I think that when you look at, for example, and I’ll pick out some examples because I think that’s the only way it works. I’m from Philadelphia. Everybody in Philadelphia, it’s a fact of life and they don’t like me saying this, Philadelphia’s market right now is totally -- and Mark’s from Philadelphia, Wharton -- I would guess if you walked down the street and asked anybody that knows anything about health care, they’d tell you that Independence Blue Cross is the dominant player in Philadelphia. They have too much market power.

Now, is that their fault? Aetna has weakened in Philadelphia in the last 10 years; other people have;
and Independence Blue Cross is extremely strong. It’s a
good, smart, well-run insurance company. Is that good
for the system there? To some degree it is. They
probably have too many hospitals bed and maybe they’re
effective at squeezing that out, but the fact is,
Philadelphia has had a lot of problems in their health
care system because they have one totally dominant
insurer. I’m not sure that’s great.

Pittsburgh, on the other side of the state,
also has a totally dominant insurance, Highmark Blue
Cross, which is Blue Cross of Western Pennsylvania, which
has way too much market power, and they’re even an odder
duck because they’re also in a hospital in a city that’s
dominated by one big hospital system, UPMC. There were
two, one went bankrupt a few years back. So, in that
city, which I don’t know if it’s good or bad, but you
have a very dominant insurer and a very dominant hospital
system. I’m not sure either one of those is great, but
arguably, both of them have way too much market
consolidation and I think it’s healthy for somebody in
the government to say that occasionally, even if it’s
just me. Hopefully, it will be you guys, too.

But these are the kind of things that I think,
as I live in these markets every day and see what’s
happening, where I could be helpful and, hopefully have
been helpful a little bit to Tim. I’ve given him a few suggestions of where to look. We, as regulators of the health care system, should be working with Justice and the FTC to say maybe there’s a problem, maybe there’s not. You are the ones that understand HHIs and all that kind of stuff and you’re the ones that should be looking at these things, not my agency. But I’ve got to see the impacts on the health care system every day.

You know, if you go to Alabama, there’s one insurance in Alabama, Blue Cross of Alabama. I can tell you, there aren’t too many hospitals in Alabama, but it’s not necessarily good that Blue Cross of Alabama has way too much market share. That’s something that, I think, regulators should look at. Maybe it’s fine, maybe it’s not. But it’s the kind of flag that should go up and we should look at it and tell people, Blue Cross of Alabama has too much market power. Maybe we should make damn sure they don’t start buying up the few smaller competitors that are left.

I can tell you from personal experience -- and they won’t like this one either -- but I was on the Board of Oxford Health Plans for eight years, and if you go out in Long Island, it’s not quite so bad in New York, there are two health care systems in Long Island. There’s probably 30 hospitals. Two health care systems. It’s
about as close to a group boycott as you’ll ever see. They have driven all the Medicare managed care plans out of Long Island. They have way too much market power and they throw it around like a ton of bricks. I would not say -- I’ve had to beg Empire Blue Cross, for instance, to stay on Long Island the last couple of years because they’re getting squeezed out by the two hospital systems in New York. That’s not healthy. That’s a bad thing.

Now, does it meet your indices, I don’t know, but I sure as hell hope somebody looks at it because they need to be looked at.

You know, I know they already lost the Inova case across the river in Northern Virginia. I like the guys that run it, they’re very nice, but I’ve lived in Northern Virginia for 25 years and you’ve got to drive a hell of a long way to get to a hospital that’s not owned by Inova of Northern Virginia. That’s probably not a good thing.

I know that the lawsuit that they lost defined that as the Washington, D.C. market. I can tell you, if you live near Mount Vernon, that’s not the Washington, D.C. market. Now, that may be a different thing in that, you know, I know the history and probably the track record of picking cases, which you guys weren’t here for the last 10 years, I was involved in Poplar Bluff, that
was probably the wrong case to pick. The hospital
distory is not great. But the fact that whether you win
cases or not, the fact that Justice and FTC look at this
and at least keep people honest on the margins to make
sure nobody gets too strong in a region is critical.

Because I can tell you market by market where I see
either hospitals or health plans, or Tim’s been very
active in some of the group practices on the physician’s
side, when any one of those three legs gets too strong,
it distorts the market and prices go up and consumers
lose, and I think that’s a big, big, big problem.

So, I don’t mean to pick on particular spots
here today, but there are ones that I’m aware of, and I
don’t get to be the regulator, you guys do, but I do
think -- I have tried with Tim especially with my agency,
to get -- we’ll supply all the data you want and we will
continue to keep saying when we see little problems
competitively, we see prices going or we see competitive
problems in the market, we’re going to be very aggressive
by telling the FTC places to look. If there’s not a
problem, you’re the ones that get to decide that.

But my view is it’s our job to try to do the
best we can to make Medicare better, more reliable, less
aberrant players in the market. It’s your job,

hopefully, to make sure the market has the right balance.
We’ll try to distort it as little as we possibly can, but I think in the last 10 years, one of the real missing links in making the health care system work efficiently has been antitrust and I think it’s very nice to see two players back on the field. We’ll provide as much as we can to help you out, and I’d like to see it be a very happy, healthy partnership, even if there’s a little bit of a competitive tension between the two agencies. We’ll help both of you.

And I say that as, I hope, a friend of the health care industry because I think healthy hospitals -- hospitals don’t have great margins, doctors aren’t real happy these days, and health plans, at least in Medicare, have been dropping out and I would say the health plans, it’s been a tough few years in the health system. But no matter how that happens, we’re still getting 11 percent a year inflation, and for the government to keep those competitive tensions as tight as they can between, I think, the three big players in health care is pretty critical.

So, I will tell you, just to wrap up, the other day, Bob Novak came by to have lunch with the Secretary and I joined them and his opening question to me was, Scully, did you take that picture of Stalin off the wall of HCFA? And I’m trying to do the best I can to change
the image of my old Eastern European agency, and we’ll do
the best we can to try to help you do your part to get
health care back to some sense of the market equilibrium.
So, thank you very much.

(Applause.)

CHAIRMAN MURIS: We will now take a short
break, and, David, what is short? Ten minutes?

MR. HYMAN: Yes.

CHAIRMAN MURIS: We’ll take a 10-minute break
and then we’ll reconvene. Thank you.

(Whereupon, a brief recess was taken.)

MR. HYMAN: I neglected to introduce myself.
I’m David Hyman, Special Counsel, and the sorcerer’s
apprentice for this exercise.

The weather is obviously a matter of some
concern. The principal issue is we’re concerned about
the Friday sessions because we have people coming from
out of town. We have not yet made a decision as to what
we’re going to do on Friday. We will make one, I expect,
by 5:00 and post it on the web sites and make an
announcement about it tomorrow. Currently, we’re
planning to go forward with the entire set of sessions,
but subject to the possibility of rescheduling the Friday
session. So, I just wanted you to be aware of the status
of that.
I’d like to now turn this over to Leslie Overton, Special Counsel as well, but at the Department of Justice.

MS. OVERTON: Good afternoon. Thank you all for being with us today. I’m, again, Leslie Overton from the Department of Justice. We’re very fortunate to have three esteemed experts with us this afternoon who will present framing presentations. Biographies are available in your materials, but let me just give you a little bit of information.

First, we will have Dr. Paul Ginsburg, who is President of the Center for Studying Health System Change. That organization was founded in 1995 and it conducts research to inform policy makers about changes in organization and financing and delivery of care and their effects on people.

Next, we will have Dr. Mark Pauly, who is one of the nation’s leading health economists. He currently holds the position of Bendheim Professor and Chair of the Department of Health Care Systems. He’s also a Professor of Health Care Systems, Insurance and Risk Management in Business and Public Policy at the Wharton School at the University of Pennsylvania, and a Professor of Economics in Penn’s School of Arts and Sciences.

Finally, we will hear from Dr. Martin Gaynor,
who holds the E.J. Barone Chair in Health Systems Management and is Professor of Economics and Public Policy in the H. John Heinz, III School of Public Policy and Management, the Department of Economics, and the Graduate School of Industrial Administration at Carnegie Mellon.

Please join me in warmly welcoming our esteemed experts.

(Applause.)

DR. GINSBURG: Well, thank you. I’m really pleased to be here, to come and present some of the findings that we’ve obtained over the years, but particularly in recent years from our visits to a representative selection of 12 health care markets in the country. I call it the State of Competition in Local Health Care Markets and I’m going to make these three key points.

One is that the rise and fall of managed care throughout the 1990s has had a significant effect on competition today. So, history matters in health care markets.

The second point is that there are forces that are outside of the purview of antitrust enforcement that have influenced competition and many of these other factors have limited competition.
And the final point is that many markets have only limited prospects for effective competition and we need to think about that and adjust to that.

Just a brief word on the Center. Leslie Overton said what we do. I want to mention that we’re funded by the Robert Wood Johnson Foundation and our emphasis in our research is on health care markets, and you’ll find a copy of this presentation and a lot of other things on our website, hschange.org.

A few things about our site visits, we do them to get some insights into changing market trends and I mentioned the 12 markets. We go to the same markets every two years so that we can track them. We chose them through a random process, the sampling frame was metropolitan areas with 200,000 population or greater. When we go to a particularly large, a consolidated metropolitan statistical area, we choose one of the primary metropolitan statistical areas as our site.

This slide is out of date, saying what our most recent visits were. We’re in the middle of a round that began in September of 2002 and will be completed in late April of this year. When we go to a site, we conduct a large number of interviews with a broad section of local health system leaders and we triangulate the results, meaning that we don’t take anyone’s word for what they
say. So, when the hospitals are telling us about their relationships with health plans, we’ll also hear it from the health plans’ perspective, and we always do this before we can gain confidence in saying something about what’s happening in that market.

Here are the sites, briefly. They reflect where the population is. And just briefly, what I'm going to do is after talking a little bit about this history, the experience of the 1990s, then I’m going to talk about hospitals, about physicians, about insurers and then about provider-insurer relations, say a few things about purchasers or employers who buy health insurance for their workforces because they play an important role in the nature of competition in local health markets, and then talk about the overall potential for competition.

I’ll talk about the 1990s briefly. I think the key -- there really are two parts of the 1990s. There was the ascendancy of managed care, which brought with it narrow provider networks, risk taking by providers, authorizations for services, and they became core components of health care financing. National and regional managed care plans were formed and they expanded vigorously during this time. Hospitals formed systems and they consolidated. Managed care and Medicare cuts
both put very significant pressure on hospitals to contain costs and probably the mid-1990s was the height of that pressure. And physicians, basically, you know, they seem to be the losers. They chafed at the loss of autonomy and the loss of income as a result of the growth of managed care.

Then came the retreat of managed care, spurred by the combination of a backlash against managed care by consumers and by physicians and this happened to come at the same time as our economic boom. The very tight labor markets, high profitability, I believe, let employers be particularly responsive to this backlash. This has led to changes such as broader provider choice, fewer requirements for authorizations and reduced use of provider risk contracting.

Providers responded in very important ways to managed care or to the retreat of managed care. For one thing, many of the structures that were developed, some of the integration -- we used to have the term "integrated delivery systems" that were formed to prepare for restrictive managed care with risk contracting, all of a sudden didn’t have a purpose in the market and they have started to unravel. One thing we’ve noted in another study is that the various hospital mergers that were particularly frequent in the mid-1990s, tended not
to follow through when it came to clinical integration
and ultimately providers have regained the leverage with
health plans that they had lost.

Now, I’m going to turn to some of the most
recent observations. For one thing, we see a real
slowing of the trend of hospital consolidation and
there’s national data that show a sharp decline in
mergers and acquisitions in recent years.

Some of the reasons for it: Well, for one
thing there are fewer players left, fewer potential
mergers. There are many communities where there are only
two hospital systems and it’s apparent to those two
hospital systems, no, we won’t be allowed to merge. So,
no more mergers in those communities.

Managed care is less threatening and I believe
that a real stimulus to hospital mergers in the mid-1990s
was the fear of not having leverage in dealing with
managed care plans, and particularly now that managed
care plans are pressed to have broad provider networks,
particularly for hospitals that, in a sense, this is not
that much of a force for mergers anymore.

A third consideration is that there’s less
excess capacity in the hospital system now, both because
some capacity have been taken out of the system. As
motivation to take excess capacity out of the system, and
more recently, hospitals have experienced increasing
demand, increasing rates of use and they’re filling up.
Often they’re limited by the number of nurses they can
recruit rather than their physical capacity. So, in a
sense, where mergers were sometimes a useful mechanism to
get some excess capacity out of a hospital system, they
don’t need to do that today.

Hospitals today are focusing a lot of
competition on what I call perceived quality, in a sense,
not what Tom Scully was talking about of measured
clinical quality, but really various perceptions of
quality. There’s vigorous competition in some
consolidated markets, but much of it is on non-price
dimensions.

In the 1970s, economists and others talked
about a medical arms race and people are talking about
that today again. What we’ve seen in our sights is very
aggressive activity on the part of hospitals to expand in
order to provide a full range of services in all of the
geographic sub-units in the metropolitan area. They want
to be able to serve everyone. We’ve also seen a focus
towards the services that are most profitable.

One thing that I’ve been struck by ever since
1995 when I started going and interviewing leaders in the
Cardiovascular services. After that comes orthopedic services. And hospitals are going where the money is now as far as this is where they’ve emphasized their expansions. We’re also seeing a sharp increase in promotional activity, a lot of advertising, both that our hospital is better than the other hospitals and also, I think more recently, advertising, I think you need this, you might want to come in and take our special heart screening for only $49.

So, all of these activities, as far as a consolidated market where the hospital systems are competing, it seems, quite vigorously, on the dimension of perceived quality or non-price dimensions is Cleveland, where we’ve really seen all the ones that I’ve mentioned on this slide.

Now, hospitals which traditionally are considered not to have much of a threat of entry by competitors, many of them perceive that they’re facing a very significant threat today by the entry of specialty facilities, and I’m talking about heart hospitals, orthopedic hospitals and ambulatory facilities that also specialize in one or both of those services.

This focus on the profitable services that I mentioned before, I believe a part of it is flawed
signals that the payers are sending into the market. The payers have never intended that cardiovascular services be more profitable than other services, but I think for various technical reasons, that seems to have happened.

I ask people about it periodically and one of the things most convincing to me, but I don’t know for sure, is that, well, you know, we set the rates -- see, this is Medicare, then Medicare sets the DRG rates and that, you know, after the -- but their productivity gains are much faster in cardiovascular services so that, in a sense, the rates become obsolete fairly quickly and these pricing distortions probably didn’t matter that much a number of years ago. So what if the hospital was paid too much for cardiovascular services and too little for, say, medical admissions. But now with specialty facilities, it is more important and these pricing distortions may be a significant driving force towards that.

What we’ve seen as far as specialty facilities is, for one thing, hospitals have used it as a tool to invade other hospitals' geographic turf. One of the markets we’ve studied, Indianapolis, on the surface looks competitive in the hospital market. There are four significant hospital systems. But when you go there, you learn that each of them kind of has a geographic area
that they are the dominant hospital in. Well, there’s been a lot of activity of building specialty facilities in the other hospitals' backyards. So, in a sense, the industry is being entered.

Of course, what really bothers the hospitals is a threat from physician-owned facilities and that bothers them because of the potential of physicians to be selective and admit the most profitable patients, the privately-insured patients, or in the case of orthopedics, auto accident injury patients, to the specialty facility that they are a part owner of and admit their Medicaid patients to the general hospital.

Certainly, this threat for specialized services does have the potential to erode some of the traditional cross subsidies that the health system is run on. So, in a sense, hospitals today are counting on extra revenue from, say, cardiovascular services to fund their emergency room or to fund uncompensated care for uninsured individuals.

In some areas, the plans have been resistant to contracting with the specialized facilities usually because of concern of, well, you know, more facilities are going to lead to more volume and, well, maybe the quality won’t be there. I know in Lansing, this was about four years ago, Michigan Blue Cross-Blue Shield
refused to contract with some ambulatory surgical facilities and, in a sense, it was pushed to do this by the major employers and the United Auto Workers Union who thought this was going to be a negative thing for health care in the Lansing market.

Turning to physicians, now, we’ve seen a recent trend of physician consolidation into single specialty groups. I think probably the most key motivation has been to achieve the scale necessary to purchase profitable equipment, that as technology is changing, you know, there is increasing numbers of tests or procedures that can be done on an outpatient basis, and one of the reasons for forming such groups is in order to be able to provide those services within the physician practice, and in a sense, the facility fees for these services may be much -- have much more of an impact on the bottom line than the professional fees that the physicians are earning for their services. Also, increasing leverage with health plans, I’m sure, is a consideration.

We have not seen a growth of multi-specialty groups, and this may be part and parcel of the retreat from restrictive managed care that the potential of multi-specialty groups is to truly integrate delivery, but people are not valuing that in the marketplace now.

Also, and this is no surprise, we see a sharp
decline in physician hospital organizations. There really isn’t anything left for them to do because risk contracting that screens plans and providers has declined so much, probably more at the initiative of the providers than of the plans, but sometimes the plans as well have given up on that.

Talking about insurers, I think much of the consolidation that we’ve seen has been across markets and that there just haven’t been that many opportunities for significant consolidation within markets. There have been some opportunities for national plans to enter markets through purchase of hospital-owned plans. In some communities, you know, back in the early 1990s, hospitals started health plans, they started it because they saw health plans being very profitable. Why can’t we get those profits? I don’t think any hospitals are trying to do this today, but some of them actually had reasonably successful health plans and this is the way that national insurers enter a market.

But in our markets, particularly the smaller ones, we’ve seen many examples where national plans entered the markets and they didn’t succeed, or at least they weren’t able to build the market share they had hoped for and they have since exited. You know, it’s hard to -- examples actually we’ve seen are both Little
Rock and Greenville where national plans have tried to enter the market, these are markets with dominant Blue Cross-Blue Shield plans, and they haven’t succeeded. It’s possible that the insurance underwriting cycle played a role in that, in a sense they entered the market when insurers were expanding into new markets and they left when insurers had a different attitude on that expansion, that they weren’t that active in pursuing things that weren’t profitable that might be profitable in the future.

Most of the plan mergers have been across markets and I think they’re oriented towards scale economies and information technology, care management technology, economies in marketing, but I think that these scale economies are difficult to achieve, and frankly, I’m struck at the rate of mergers across markets, given that it’s so much easier to achieve these economies within a market than across markets.

Health plan competition today, given our attitudes about managed care, a lot of it focused on product innovation. Plans are customizing their products for diverse employers. They’ve always done this for self-insured employers. They’re increasingly offering fully insured products with more and more variety.

Plans basically are competing with other
vendors. You know, they’d like to do disease management, but some employers instead will decide they’re going to hire their own disease management vendor rather than use the health plan’s vendor. And, actually, there probably are some of the specialized services that plans provide that are more open to market entry than to the basic service of assuming risk.

A lot of emphasis today is going into case management of identifying with modeling often. Those enrolled individuals most likely to have serious illness and to be very expensive and to intervene early with some of the preventive services appropriate for their condition, and certainly with consumer-driven plans and other trends to more cost-sharing plans are working very rapidly to develop benefit structures that are novel, new types of patient financial incentives and also tiered networks.

Customer service is a very important dimension. It kind of reminds me of what hospitals are doing with perceived quality. But plans cannot afford to have poor customer service.

There’s a Wall Street term called “pricing discipline” which I think we seem to be seeing now, and by that, the Wall Street analysts mean that plans are not attempting to buy market share by lowering their price.
the way they were in the mid-1990s.

Blue Cross-Blue Shield, we see they’ve solidified their dominance in some markets. Now, they have a history of large market shares in many markets and they have benefitted recently from a shift in consumer preferences towards broad networks and they traditionally have emphasized broad networks and preference for PPOs versus HMOs. Blue Cross-Blue Shield plans never really put that much emphasis on HMOs. So, in a sense, the market is coming back to where they’re traditionally strong.

Consolidation in the Blue Cross-Blue Shield world is intertwined with conversion. One thing we’re seeing now is that the states have become less resistant to efforts by Blue Cross-Blue Shield plans to convert to for-profit status, and I think a factor in this is the potential to gain state revenue in the process. In the early days, in a sense, the value of these non-profit enterprises went to foundations. I think, today, it’s much more likely to go into state treasuries and I don’t see that as being unreasonable because they’ve had tax advantages from the states for a long time.

I don’t know what I meant by greater attention to price. Oh, yes. There’s been a lot more attention to the prices paid and the prices paid out in these
conversions and right here in Maryland and D.C., we can read about that in the newspaper. There’s certainly a split within the Blue Cross world about the virtues of conversion. Some of the plans in our markets seem to be very committed to maintaining their non-profit status long term, while others, of course, have converted to the for-profit status.

Talking about relations between insurers and providers, hospitals are gaining leverage over plans. A key thing is the must-have status of leading hospitals that, today, with the demand for broad networks, if a network does not have a prominent hospital, it is not that viable in the market and hospitals have recognized the power.

The fact that hospital capacity is constrained is also relevant to greater leverage and, in fact, we have seen instances in our sites where hospitals have resisted tiered networks, such as in California, basically by threatening not to contract with the plan if they’re placed in the lower, less attractive tier.

There is evidence of moderately higher price trends for hospitals using the producer price index, hospital component for non-Medicare and Medicaid services. Hospital prices were going up at about 2 percent a year, around 1998, 1999. In 2002, the first
nine months, they were up 4.7 percent in that year.

This is not that sharp an increase in price when you consider hospital wage trends, that as a result of shortages of nurses and others, hospitals have, in fact, been paying much higher wages.

Basically, there are three possibilities of why the trend seems so moderate. Well, for one, maybe the numbers aren’t that accurate. These numbers are not easy to do accurately. Number two, it’s possible that ordinary hospitals aren’t doing as well as prominent hospitals and we certainly have a lot of anecdotes about prominent hospitals having price increases a lot higher than 4.7 percent. And the other thing is that maybe prices are heading a lot higher and we just haven’t seen it yet. We’ll have to look at that.

Now, physician leverage vis-a-vis health plans has grown less than hospital leverage. I believe the reason is that the brand name status carries less clout for physicians in dealing with insurers. You know, if there are three hospitals systems in a community, it’s a lot more noticeable not to have one of those three than to not have 20, 30 percent of the physicians in a market, including prominent individuals.

A key exception for this is in some single specialty groups where they have sufficient market share
or reputation that they do have a lot of leverage with insurers. For the most part, in negotiations, most physicians continue to be price takers. The plan says, here’s my price schedule, will you sign up or not. And you don’t have the negotiations that you have with hospitals.

Again, if you look at the producer price index for physician services for non-Medicare, Medicaid, that suggests that the price trend for physicians has remained very low. You just don’t see an increase like you do for hospitals.

There is a trend towards physicians leaving networks and managed care plans, and in some areas, establishing boutique medicine practices. There are a lot of anecdotes, although I don’t have a good sense about how important a trend this is. We heard about it most in Seattle and in Boston.

Purchasers, employers that buy health insurance, have influenced the nature of plan and provider competition. I believe their demand for broad networks is a very significant thing. We’ve seen in our sites, employers taking sides in some of the well-publicized showdowns between hospitals and health plans. And in one in Boston, I guess a couple of years ago, the employers clearly took the side of the hospital and they
told the health plans, you better have Partners in your
system or we’re leaving you.

More recently, we’ve seen some examples in
Lansing, Michigan and in Seattle where the employers have
supported the health plans in this sense and egged the
health plans on about don’t meet that hospital’s demands.
We’re going to stick with you.

The shape of the benefit package is very
important as more financial incentives work into the
benefit package, this is going to set the stage for a
possibility of more competition on the basis of price.
And a final thing is employer willingness to pay for care
that is of higher quality when it can be measured. And
traditionally, employers haven’t been willing to do that,
but there are some very well-publicized demonstrations in
some states where specific large employers have gotten
together with their insurer and told the hospitals, if
you meet these requirements, we will pay you more per day
or per case than we would otherwise.

Purchaser behavior is changing. There never
was the amount of collective activity in communities of
large employers that people thought there were, but it’s
definitely declined since we started watching it. Some
of the things that have led to it have been national
mergers among employers, because it seemed as though the
only time you had significant collective activity by employers was when there were headquarters of a number of large corporations.

HR departments have been slashed and, perhaps, the lack of success at some of the coalition activities that employers have pursued has influenced the decline today.

I believe that purchaser behavior does follow economic cycles. It depends on the profitability of employers in the economy and the tightness of labor markets, and now we’re probably in somewhat of a middle range. Certainly, there’s more concern about costs than there was three years ago among employers, but not as much concern as there was in the early 1990s when the very large shift towards managed care began.

We don’t see much competition based on clinical quality, and I think as Tom Scully was pointing out to you, the lack of information is a real barrier. Experience with hospital report cards, when we’ve seen them, has been that the hospitals pay a lot of attention to them and they actually have a beneficial effect from hospitals seeing where they’re weak and looking into why they’re weak and trying to do something about it. We often don’t see much use of report cards by employers or consumers and hospitals have been resistant to them and
have closed down some efforts.

We’re seeing a private regulation approach of the Leapfrog Group in a sense saying hospitals should have these processes which we believe lead to higher quality and employers are pushing hospitals to meet Leapfrog standards in some communities and not others.

I think it’s clear to me that as far as providing information, the government may need to act as a catalyst. In New York State, they’ve done some very valuable work with open heart surgery as far as providing quality information, and I believe that CMS is going to be the key player and their leadership in doing this has the potential of being very important.

Many markets, it seems to me, have limited potential for price competition. There are a number of markets where there are small numbers of hospital systems, small numbers of health plans. Entry seems to be difficult, meaningful entry in both cases.

There certainly are some limits on the degree to which you can use consumer price incentives. You can only push cost sharing so far. We’ve got this limitation as far as useful information and also leaders in communities are concerned about the cross subsidies and protecting them.

How can we deal with the absence of competition
in some markets where it’s not an antitrust enforcement issue? Well, for one thing, I can envision, at the community level, some informal public utility type pressures and these perhaps can prevent some of the more egregious behavior. You know, many hospitals are non-profit and they’ve got employers and other community leaders on their board, but I think this is unlikely to meet some of our other goals for competition.

The Medicare payment policy which Tom Scully called his price control -- he didn’t use those words, but anyway, this is something that even if there’s not much competition in the marketplace, Medicare and Medicaid are a large enough share of many hospitals’ revenues that those systems do provide incentives to cut costs even if the incentives aren’t strong from the private insurers, and there are alternative options. I don’t know how realistic they are of a 1970s type regulation of resources or rates or a significant increase in patient financial responsibility.

Thank you.

(Applause.)

DR. PAULY: Thank you. Well, I’m the aforementioned Mark Pauly from Philadelphia and Philadelphia has changed a lot. A lot of people have outdated ideas about Philadelphia. For example, you may
think that the slogan for Philadelphia is the City of Brotherly Love. It actually isn’t. Some relative of some alderman got a contract about 10 years ago to come up with a new slogan for the city. This is the honest truth. The slogan is, Philadelphia, the City that Loves You Back. However, recently, people have been pointing out that when tourists come to town, especially in their cars, and if they happen to, by mistake, cut off local drivers on the freeway, they may not perceive Philadelphia as the city that loves you back. And so, there’s a competition for a new slogan, honest slogans about Philadelphia.

So, my proposal is to put on the signs coming into town, Philadelphia, the Home of the Health Insurance Duopoly. At least that would be truthful. And that sets the stage for some of the things that I want to talk about today, which does have to do with the general idea of, as the title says, Competition As An All-Purpose Remedy For Medical Care and Health Insurance. And I'm trying to respond to the questions that were asked via David and via the Commission and the Department to offer some general observations on things that are different about medical care and whether or not those differences preclude the application of standard competitive ideas.

I guess my punch line actually is, medical care
is different, but it's not that different. Having said that, though, on the other hand, there are some considerations that need to be taken into account in applying kind of our standard theory of the desirability of competition to the medical care sector.

About 20 years ago, I wrote a paper called, Is Health Care Different, and I think I haven't changed my mind on some -- I still agree with myself. And one of the things I said there was that by my back-of-the-envelope reckoning, about 20 to 25 percent of medical care actually looks pretty much like ordinary markets, kind of like apples and oranges and haircuts and things like that. There are a lot of medical services that you don't have to be an epidemiologist or a physician to evaluate that people buy fairly routinely and that at least they pay enough of the price that they would pay attention. So routine pediatric care, private nursing home care would be such examples.

But that leaves a large share of the market which is not like that, and probably because of the spread of health insurance, the fraction of the market which is like an ordinary market, has changed. So, it's worth thinking about how different it is.

The perspective I'm going to take here is, I guess, at the other end of the spectrum from what Paul
was talking about. He was talking about what's actually happening out there, and basically, I'm going to be talking about, sure, it happens in practice, but can it happen in theory. Or to talk more generally about the applicability of kind of standard economic ideas to the health care sector. In general, it's my perception that when it comes to a competition policy, either about mergers as enforced by the Justice Department or about competitive behavior as enforced by the Federal Trade Commission, economic theory and the law, or at least the law enforcement agencies, pretty much march arm in arm.

The economic idea of maximization of a welfare-weighted sum of consumer well-beings actually seems to pretty well coincide with the intent of the law to break up a monopoly and prevent monopolization. But it doesn't always work that way. So, I'm going to spend my time talking about the hard cases, the ones where when it comes to health care, and to some extent, when it comes to economics itself, as illustrated in health care, some of those simple ideas would not necessarily carry over.

So, the general premise here is competition is good when it comes to apples and oranges and a fair amount of health care is actually like apples and oranges. But some of it isn't, and so, that's what I want to worry about. And what I'll argue, though,
nevertheless, so you don't get too depressed, is that in
those circumstances in which competition can't be shown,
at least on a theoretical basis or with empirical
evidence to be the correct answer, there's something you
could call Competition Plus, which probably is. And
another way to say that, that's sort of the good news
version of it.

The bad news version of it is competition is
necessary but not sufficient for maximization of consumer
welfare in a lot of circumstances in health care. We can
identify what the other things are. That's sort of the
good news. The bad news is, the other things that need
to be done to accompany competition may not be under the
jurisdiction of the Justice Department or the Federal
Trade Commission. They may, for example, be under the
jurisdiction of the Treasury Department or some other
part of government. So, no single agency -- any single
agency trying to improve welfare on their own is going to
have to either be restricted or get some cooperation.

So, that's the basic question. Competition
improves welfare in the Econ 101 model and the question
is, will it work as well in medical services and health
insurance markets? Basically, what I want to do is
identify the exceptions and talk about them and talk
about how far you can get? How much of a plus do you
need? What do you need to change?

In general, I'm going to give competition the benefit of the doubt. So, I'm not going to -- at least I haven't given myself the charge, because I know I couldn't do it, of proving beyond a shadow of a doubt that competition will make us as happy as we can possibly be. You can never prove that, and if your alternative model is one of, as Paul was mentioning, either a public utility type regulation or some other kind of arrangement administered by angels, it will always do better than the market, which is bound to still have a few glitches. But I'm going to at least assume the absence of angels for purposes of discussion this afternoon and, as I said, try to get things to be reasonably competitive and then call that good enough for government work.

So, which markets -- there's actually two markets to talk about and they are, obviously, the market for medical services and goods and mostly I'm going to be talking about medical services. The most important medical good, of course, is prescription drugs. It's protected largely by patents and has actually been a major source of the recent increase in health care spending, but at least for purposes of today's discussion, I'm not going to try to think about competition policy in the pharmaceuticals market.
Then the other is the market for health insurance and with about 86 percent of health expenditures paid by third parties, I had to say this, the two are inextricably intertwined. It's so much fun to say inextricably intertwined, but as a matter of fact, they are, and that's one of the issues, one of the circumstances in which a straightforward application of the idea that more sellers and more entry is good doesn't necessarily follow.

In fact, I might as well say at this point -- I think I didn't put it on the overhead -- for Econ majors who went beyond Econ 101, the name of the problem here is the generalized theory of the second best and the proposition in economics is, well, there's this beautiful model of perfectly competitive equilibrium and a certain set of conditions that have to hold for it to apply, free entry and well-informed consumers and no taxes or subsidies or distortions, and then you get the beautiful result that if that happens, as if by an invisible hand, everybody's welfare is maximized.

But the problem is, if one of those conditions is absent, you don't necessarily improve things by doing more of the other condition. In fact, sometimes you can get a situation where, in a sense, two wrongs make a right. Having less competition, if there's some other
glitch, might actually be better than having more
competition if you can't get rid of the glitch.

As I've already said, though, my version of
Competition Plus, which I'm trying to get a trademark on
that name, Competition Plus, envisions that you would do
something about the other thing and then do competition.

So, these are the things that I want to talk
about that potentially represent deviations from the Econ
101 apples, oranges, widget type model. Variable
quality, widgets were widgets, apples were apples.
Actually, today apples are not apples at all anymore.
They're just red blobs. But in my day, apples were
apples. But in health care, as everybody knows -- well, actually, people kind of ignored this for many years, but
as we're now talking about in great detail, product
quality is variable. A doctor is not necessarily a
doctor, a hospital is not the same as any other hospital,
even though they're all licensed by the state and
reimbursed by Medicare.

Second, consumers are imperfectly and
asymmetrically informed. Actually, the asymmetry works
both ways, if you think about it. About the process of
care, of course, my doctor knows more than I do about
what I want to get out of care. I know more than my
doctor knows about that, and we have to kind of tell each
Then insurers set prices or administer prices. I'll fuss a bit about whether we really ought to call them that, but there's some economic models of administered prices that I want to use, so I'll stick with it.

Some suppliers are not-for-profit. That must make a difference, mustn't it? I mean, the last time I worked for a for-profit firm was when I worked my way through college selling shoes. So, I probably am guaranteed not to be too nasty to non-profit firms here, but I do want to say some things that are not completely complimentary about them. And then we may, and often are in a situation -- this is the Philadelphia situation, perhaps, where insurers with market power faced providers with market power. So, that's what I want to talk about.

So, a few definitions and postulates to clear away the underbrush. Competition can obviously mean a lot of things, and I mean here the general idea of free entry by many firms subject to a break-even constraint. Whether or not that actually reproduces the perfectly competitive equilibrium of the textbook, of course, is what the discussion is all about. But at least the medicine is free entry, lots of firms subject to a break-even constraint.
This is actually a somewhat argumentative proposition from the viewpoint, at least, of some of what I heard today from Tim Muris and from some of what I saw in some of the publicity material for this session, and it's an example of where the economists and antitrust lawyers maybe aren't quite marching arm in arm.

So, here's what economists think is great. We think the best possible thing is whether arrangements maximize the sum. That should be S-U-M. I have to revise these. These were dictated rather than -- or maybe the spellcheck made up its own mind here. But the sum, the arithmetic combination of consumer and producer surpluses is what we want to maximize. Net welfare. And why that has an edge to it is that sometimes, the arrangement that does that doesn't necessarily maximize consumer surplus alone.

So, maximizing consumer welfare is not really what economic efficiency is necessarily all about and that, particularly in the case of monopsony, I'll get to, raises some issues that I think need, at least, to be recognized and thought through. And then I've talked about the theory of second best. I've already said something about that.

What competition alone can never do, it can't get all or even most of the uninsured insured. I
personally think that's the biggest problem in the U.S. health care system at the moment. Compared to that, I don't lay awake at nights worrying about the absence of competition nearly as much, although every other Thursday I do try to do that. But the problem of the uninsured, I think, for the most part, is actually not cherry picking. It's the fact that there are a lot of -- it's because of two facts. One fact is there are a lot of low-income people who have a lot better things to do with their money than spend it on health insurance, and the other is -- it's sort of the opposite of cherry picking -- there are a lot of people who don't value insurance as much as it costs. So, they don't buy it for various reasons.

Competition, alone, can never stop the real growth in medical care spending. The primary reason for that is from the beginning of time up to the present and even now, we know that the primary driver of growth and medical care spending is the development of beneficial but costly new technology.

Now, if the biomedical engineers would just stop, we could get control over health care spending, but I personally wouldn't want that. If we could make the market more competitive than it is now, assuming it's not perfectly competitive, the best thing that that would do would be to produce a one-time cut in health care
spending. But if technology continued to progress in the same way, presumably the rate of growth would be about the same. There may be some more complicated story about the relationship of competition to the rate of adoption of new technology, but that's not something I'm going to get into here.

This is why I left out pharmaceuticals. Competition alone cannot lead to optimal rates of product innovation. That's why we have patent laws and I'd certainly be willing to argue about patent protection and whether it's optimal, but that's another argument for another day.

Here again, the second to last one is also a point that, I think, is kind of my anti-PR protective shield line of thinking. What competition will do in a perfectly competitive equilibrium is give consumers the optimal level of quality, which means the level of quality essentially where the marginal benefit for improving quality more, which can almost always be done, isn't efficient to do because its marginal cost would be greater than the marginal benefit.

And so, it's perfectly possible, and I will offer some examples which I think have actually occurred in health care, to have quality that's too high rather than too low. I don't believe that is a problem for the
uninsured. But I do believe it is potentially a problem for those of us who are well-insured, well-off and well-subsidized.

And, finally, this was an attempt to say something positive with a whole bunch of negatives, but I don't think there are substantial economies of scale, the traditional justification for a natural monopoly in health care. There are a few exceptions, as Paul mentioned, the only orthopedic group in town or something like that. In some towns, of course, everything is a monopoly and there's not much you can do about it other than tell people if you want to live in Smallville, that's the deal. But most Americans, at the moment, don't live there, although maybe they should go home.

So, this is kind of what I said. Competitive markets, at best, minimize -- they do do good things. They minimize price for a given quality, so that's a good thing to do. So, you're not overpaying for whatever quality you get in an idealized competitive market. And, generally, we think they choose the optimal quality. Just in case there were some other economists here, I had to say this is not even absolutely guaranteed. In a world of a finite number of products, we're not absolutely guaranteed that competitive equilibrium will involve exactly the right products. But if you can have
a pretty big variety, you get pretty close to the ideal.

And this was the second point I made, but I'll make it again here. Compared to its absence, the introduction of competition will reduce price or improve quality, but not necessarily both. And as a little bit of a preview, in some circumstances where the market might have been dominated by a non-profit monopolist that attached very high weight to quality, you could, by having more competition occur, actually reduce quality. That would be good, but it wouldn't necessarily look good to the institute of medicine. But they're not mostly economists. And the last line is the reason.

So, what about competition under administered pricing? This is the model. Suppose some large buyer -- I won't mention the name of anybody who was up at this podium a few minutes ago, but you know who I mean -- sets the price for a product of variable quality and says this is what we're going to pay for this, flat dollars period, and then forbids or deters balance billing. So, nobody is allowed to pay anything extra. It's absolutely illegal for you to exercise your constitutional right to overpay.

Well, then what does economics predict will happen? We actually have a model for this which has been around for a long time. It's sort of got polyester pants
and long sideburns. It's the regulated airline industry competition model where the argument was, back in the days when airline fares were regulated, because airlines couldn't cut their price, they engaged in competition in non-price ways, and the poster child for a way to engage in competition that didn't sound like it was a very efficient thing to do was the pub lounge. I think that was Continental where they did some other even less politically correct things from today's standards to try to boost ridership on their airline.

But one of the things they had in a couple of places in the plane was a pub lounge where you could -- it's hard to believe thinking back -- you could unbuckle your seatbelt and go up and drink yourself into pleasure. And that was why you should fly their airline.

The comments that were made about that model at the time were, that doesn't seem very efficient because that actually led to too high a level of quality. I mean, actually, the main competitive device then was schedule frequency. There were too many planes leaving on a given day from State College, Pennsylvania. That doesn't happen anymore now that we've deregulated, thank goodness. But that was the idea.

But it still can happen and probably does happen in health care where you do have this administered
price arrangement and it is fair to say, I think, that Medicare is probably the primary source of administered pricing these days.

Personally, actually, as I was thinking about it, I think we want to wait until Tom Scully moves on, but I don't see any problem with, say, breaking big Medicare, traditional Medicare into four parts, say, you know, just randomly assign beneficiaries to four different firms, clone the CMS administrator -- we don't want to clone Tom because that's impossible, but clone some CMS administrator and have them compete with each other. That's kind of what the Germans did. I don't know if it's been too successful, but you can actually do it and then have competition.

But in any case, when you do have administered price, the general idea is that competitors do things and spend money on things that would be called quality, at least as perceived by people making the choice of what firm to patronize, that attract business that bids away profits. Is it efficient or not? Well, it kind of depends on whether you assume that you're stuck with the regulated price being where it is or whether you think the regulated price would change. If the regulated price is too high, you'll get excessive socially inefficient quality. If the regulated price is too low, you'll get
socially deficient quality, but at least you'll do as
good as you can, and if Tom can just figure out how to do
this and get the price exactly right, it can actually be
just as good as the competitive market. But that's
asking a lot of even a very unusual and accomplished
person to figure out exactly what the right price is.

We do see some evidence that this actually
happens in Medicare. There's some research that I did
some years ago, but I think it probably would still hold,
indicating that where the prices for outpatient
hemodialysis were set unusually high relative to costs,
although in the short run, some dialysis firms made
money. In the longer run, and in the equilibrium that we
were looking at, they actually competed those profits
away by doing things that attracted dialysis patients.
The main thing they did there was actually very similar
to the airline. They scheduled dialysis at more
convenient times, like at nights and on weekends.

Medicare HMOs attracted -- were able to make
money by running ads, of course, showing elderly people
square dancing, which attracted lower-risk Medicare
beneficiaries, but the evidence we have suggested that
they competed away much of those profits in additional
benefits that they provided to those beneficiaries in the
form of zero premium, prescription drug coverage and so
forth. And now that we've cut down on that cherry picking by those Centrum Silver Medicare HMOs, a lot of people are upset that they don't any longer have the same benefits they did before.

Paul already mentioned this. We used to think it also happened to hospitals in the old arms race world. We had a reason for thinking there. Because selective contracting was forbidden, hospitals couldn't compete on the basis of lowering their price and expect to get a big bump in business for that. So, they might as well compete by adding the latest machine.

Nowadays, it's not supposed to work that way, although I don't know how you feel, Paul, but I think we probably are going to pull out of it in the face of double-digit health care premium increases. But I think we went through a period there where consumers, in a way, didn't care so much about the price of health care. They cared a lot more about being able to go to any doctor and hospital in town and they kind of returned us to the arms race world that if we get miserable enough in terms of rising premiums, I think that will go away of its own accord, but we shall see.

Competition is always better for consumers, but the best thing is to get the price right or either get rid of administered pricing if you can have an actual
For The Record, Inc.
Waldorf, Maryland
(301)870-8025

competitive market of the real sort or set optimal
prices.

Imperfect consumer information can lead to
monopolistic competition even with free entry. So, it's
never going to be exactly perfect. But what are you
going to do? I mean, doctors are different, and so, it
does mean that any given doctor with any given bedside
manner or technical skill probably won't lose all
business by raising price a dollar above the going level
in town. But the best solution, which I think we've
already talked about here, is the best information and
competition.

It is true, in a second best sense, if
consumers were uninformed in a particularly biased way,
meaning they over-demanded rather than under-demanded and
they paid something out of pocket, monopoly may actually
improve efficiency, but a far better solution to first
stimulate consumer demand to a situation in which
consumers' demand is first over-stimulated by incorrect
information about medical care being more valuable than
it is, and then trying to dampen that demand by
overcharging them. It's pretty obvious it would be
better to get rid of both of those things. So, that
would be the idea there.

The most recent manifestation of imperfect
consumer information is, of course, the medical errors controversy stirred up by the Institute of Medicine. I think I'm probably just going to be saying here what a number of the other speakers have said. I don't understand if there are all these medical errors around why they exist. Other industries don't seem to have this problem. What's the problem in medical care that allows firms that continue to offer care that can kill you to continue to exist, at least if that's known and knowable? Where is the health care system that advertises not we care, but we don't screw up? It seems it's possible. And I think the debate that we are in the midst of having, and probably will continue to have, though, is what to do about it. And the alternative, of course, to informed competition is what I call a compassionate conspiracy of right thinking providers. Let all the leaders in medicine get together and agree on a set of rules and regulations and looking over each other's shoulders at self-regulation as a solution. Ultimately, you have to answer that empirically. I personally wouldn't bet on self-regulation, but it's worthwhile to think seriously about how to deal with the question of what would be the best solution to this problem, and at least show the flag for informed competition and markets as a device for improving
quality, as opposed to rules and regulations guided by former editors of medical journals and other saintly persons.

Insurance in a world of provider monopoly.

This is actually one that both Marty and I have fussed about a good bit. The general proposition which actually I wrote about when I still wore short pants is the idea that insurance, the kind we usually have, can cause over-consumption because of moral hazard. And a potential solution to that problem, if you think about it -- and this actually only holds if coverage is less than 100 percent and it takes the form of a percentage co-insurance, but if it does take that form, having a monopolist get in there and raise the price can actually cause consumers to stop the over-consumption.

If consumers could choose their insurance without any interference and without any imperfections, Marty's actually shown that the situation in which monopoly can be good for you will never arise. But in a situation in which insurance is excessive, either because the government decided that you would have that amount of insurance, as in the case of Medicare or because somebody decided we'd devote $140 billion of the Treasury's money to subsidizing health insurance for upper middle income people, then in theory, you could get a second best
solution. A little bit of monopoly might be a good thing. But, again, you can see my real plan here is to argue against the other defect. If two wrongs make a right, let's get rid of both wrongs. In this case, the tax subsidy and monopoly. It's more efficient and more just.

Suppose providers have market power. A question which actually was discussed today and which is of great interest to me is, does it help if insurers get countervailing power in the form of monopsony? I think Marty will say a little bit about this, too. Without solving for kind of equilibrium strategies, I think you can see that if you started off with providers having some monopoly power, if you had an insurer with market power that had either the wisdom or the luck to set its administered price at the competitive level and say, that's what it's going to be, boys, that would actually be better than being at the monopoly level. Quantity would expand. Quantity demand would expand because price would be lower and things would work out fine.

Monopsony, I want to make a point here, is not necessarily implied just because there are a small number of sellers of insurance. The other thing you need to have it happen is that the supply curve of care be upward sloping and it isn't necessarily, if you think about it,
for all kinds of care, like home health care. It uses a relatively small fraction of nursing personnel. There's a price that covers their cost. If you don't pay it, you can't be a monopsonist and get the price below that. People will just stop rendering it. What the supply curve of hospitals looks like, it would probably be interesting to explore.

Monopsony, though, doesn't necessarily -- removing monopsony -- monopsony is inefficient because it helps buyers less than it hurts sellers. Now, of course, if the buyer, as in health insurance, also has a monopoly in their product -- so the monopoly health insurance, the two duopolists in the Philadelphia are not only duopsonists, that's even more fun to say than monopsonist, but they're also duopolists if they're profit maximizers, you can show that's actually worse than not having monopsony at all. But at least it's possible to think about. And, occasionally, our Blue Plan argues it's like this. To think of it as not a profit-maximizing entity but a consumers' cartel, in which case, it could force down prices which could increase consumers' welfare, but, of course, would worsen producers' welfare, and on balance, we'd be worse off. So, consumers' cartel as a consumer, that's fine for me, I guess. But as somebody who teaches MBAs
who will work in the health care industry, I'm not sure I want those provider surpluses totally diminished.

How about non-profit firms? I'll try to move quickly through these. In competitive markets, of course, all firms are non-profit effectively. Among hospitals, the evidence that I've reviewed suggests that there isn't really much difference. For other services, like nursing home care, it looks like for-profits may be better, at least in terms of quality and efficiency. At least in terms of quality, at least there's something good to be said about -- I'm sorry. Non-profits may be better in things like nursing home care, dialysis units and so forth, at least in terms of quality. I don't know about efficiency. It seems like non-profit ownership and insurance -- Paul did some of this work years ago -- it doesn't seem to have any socially redeeming value.

I think I've already said this -- oh, no, I haven't said the first one. Monopoly is bad if the not-for-profit is a for-profit in disguise or a doctor's workshop. So, just because a hospital is nominally not for-profit, at least we've speculated, and nobody has proved to the contrary, that it might not actually be setting the price a monopolist would set and then, in effect, using the money either to enrich doctor's -- there's a complicated story of how that can be done -- or
even if it's run in the interest of the Little Sisters of
the Poor, so you're setting monopoly price in order to
maximize charitable contributions, that's still bad for
consumer welfare and there's a way to improve efficiency.
That's what the second point says.

So, my conclusion is that Medical services and
health insurance are not so different. After all, for
one thing, people are people, and for another thing, they
respond to incentives. So, most of the time, it's just a
matter of getting the incentives right as usual. The
whole world looks like that to economists.

Secondly, though, while there are some
differences, more competition is usually the best
medicine and I guess this is the primary take-home
message. When competition isn't the best medicine taken
alone, which is sometimes the case, it usually is best if
combined with something else.

Thank you.

(Applause.)

DR. GAYNOR: Great. Well, that sounds two
cheers, maybe two-and-a-half cheers for competition on
Mark's part. I'm from the other monopsonized,
monopolized market at the other end of the state of
Pennsylvania, Pittsburgh, in which we have one dominant
health insurer and one dominant hospital. I don't know

For The Record, Inc.
Waldorf, Maryland
(301)870-8025
if that's why we were chosen to constitute two-thirds of
the panel here today, but it does make for some intrigue.

Thanks, I'm very glad to be here. I think the
Federal Trade Commission and the Department of Justice
are to be commended for reemphasizing health care as an
area of enforcement and for holding hearings in this very
important area.

Before starting my presentation, I thought I'd
start off by reading you my horoscope from today. It so
happens, I got here early and I happened to glance at it
in the Washington Post. I read the most important part
of the Post first, the sports, and then I moved on to the
funny pages. It just so happens, the horoscope caught my
eye and it seemed fitting for today's activities. Now,
this is a horoscope by Sydney Omarr for Gemini for
February 26th, 2003. The day features an aura of mystery
and intrigue. You have a right to know where money and
other valuables came from and where they ended up.

So, what does that have to do with these
hearings? Well, I think it has something to do with
them. To some, how health care markets work is a
mystery. I think Mark's done something to clear that up
and I hope to do a little bit of that today. Intrigue,
well, any time we're talking about antitrust enforcement
or perhaps activities along the Potomac, we're certainly
talking intrigue to some degree. Now, I suppose today's and the next couple of days' activities are unlikely to make it into the Spy Museum elsewhere in town, but there's certainly some element of intrigue. And you have a right to know where money and other valuables came from and where they ended up. Well, this is what economists do. Where did the money come from and where did it go? Other valuables, well, quality is certainly one of the most important areas that we're going to be talking about today, and so, I thought this was particularly fitting.

Let me start giving you an outline. Microsoft, being the evil empire, did something to change the little logos here in my Power Point slides. I don't know what these happy faces are, but I can assure you, I did not put them there. But that's a monopoly of a different stripe and that's not my topic today.

So, let me lay out what I'm going to cover in my talk. I'm going to talk about some general issues surrounding competition and health care markets, and Paul has laid out a lot of facts for you and Mark has very ably covered the waterfront as well. So, I'm not going to attempt to cover all the issues. I'll focus on the issue of whether antitrust enforcement makes sense for health care markets. I will then move on to discussing quality and competition in health care markets, which is
the labeled focus of these hearings. In particular, I'll cover what I think we know and what we don't know about this issue, and then ultimately what this means for antitrust policy in the large and in the small.

So, general issues on health care markets, is health care different? Well, yes and no, on the one hand and the other hand. I haven't found a one-handed economist as of yet. Health care is not like a perfectly competitive textbook market. So, that's a yes, but on the other hand, almost nothing is. This sort of comparison, in some sense, is trivial. Almost all markets are different from a textbook perfectly competitive market.

The markets for computer operating systems and cement are very different, right? We can think of lots of ways in which they're different and I don't need to explore those for you. That implies different economic analysis if we want to understand how those markets work and, of course, different antitrust analysis and treatment.

Now, on the yes side, health care has some specific characteristics we must take account of in economics and in antitrust. Now, at one level, this is certainly consistent with a standard antitrust view of case specific analysis, right? Each case is unique, the
facts are critical and while I say there's no single aspect of health care as a product or market that is unique in and of itself, there are other markets with asymmetric information. There are other markets with insurance. There are other markets with variable quality.

Health care is unique in having a particular constellation of these characteristics and in their importance. Quality, in particular, is prominent in health care. Not in all kinds of health care as Mark said very ably. There's actually a large chunk of services bought and sold that look pretty much like any other kinds of service. But there's certainly services for which quality variation is large and that variation is particularly significant.

Can markets give us what we want in health care? We're asking the question, is health care different, can health care do the job? We're very comfortable with markets doing the job for us with things like pencils, food. What about health care? This is 100,000 foot policy question, if you will. Well, let me back up. There is a 100,000 foot policy question about whether we want a market system or not for health care in the U.S. Let me suggest that this is not on the table at present and won't be for the foreseeable future, which in
Washington, of course, means the next election.

So, at present, we rely on a market system for health care. The presumption of antitrust is that competition is good and, in particular, unregulated monopoly is bad, and I'm going to come back to thinking about a monopoly as an alternative throughout my talk. So, the question is, is this true for health care because that is presumption of antitrust?

Well, let's think about two alternatives. I'm not going to suggest these necessarily exhaust all of the alternatives, but two alternatives. One extreme is no regulation at all, period. Completely unregulated markets. So, there's a possibility of an unchecked monopoly. I think that this is something that most reasonable people can agree that completely unchecked monopoly, unregulated monopoly, is bad. Regardless of how well you like markets or not, you probably don't like the idea of monopoly with no checks on it whatsoever.

So, another alternative is self-regulation. So, we can let the market participants regulate themselves, again, without any interference by government authorities, enforcement agencies in particular. In other words, let physicians and hospitals police themselves. There are various proposals that amount to this, at least in some form. There's been legislation
proposed to exempt physician practices from the antitrust laws, the Campbell Bill of a Congress or two ago, Barr-Conyers, another version of that. The quality improvement movement presumes that it's all done by the profession and ignores markets.

Now, this presumes that physicians, say, care about patient well-being and will enforce behavior among themselves that maximizes social welfare. It certainly takes care of patients' welfare. Another way of thinking about this, well, could we put Marcus Welby in charge? Well, how likely is this to give us what we want? I think there are some very serious flaws with this.

Doctors certainly do care deeply about their patients, but I don't think it's a bad thing to say that other things matter to them as well. There's nothing wrong with that, but then that's going to make reliance on self-policing problematic. There are going to be temptations to do things, for example, that increase income at the expense of patient welfare, even if that doesn't mean, and particularly, if it doesn't mean compromising the health of patients. So, even Marcus Welby might do the right thing by his lights, but end up doing the wrong thing for society.

Further, inclination among physicians is to focus on medicine, not money, which again makes an awful
lot of sense. But patients care about money as well as
medicine. Self-regulating doctors, like any other self-
regulating profession industry, may not do a very good
job of balancing these things.

We probably want physicians concentrating on
medicine. At least, I think, when I see my doctor, I
think that's what I want him concentrating on. Last, I
think professionals have a hard time regulating
themselves. Of necessity, there is a great deal of
individual situation-specific judgment that's called for,
and this implies a lot of individual independence.
Again, I think that's the nature of the beast and want a
lot of that. But that means a couple things. It's going
to be hard to detect problems, it's going to be hard for
colleagues to discipline one of their own.

So, where firms' goals -- and firms you can
think here are physician practices, hospitals, insurers,
any of the market participants -- conflict with those of
society, which will win? And I'm not suggesting that we
absolutely know the answer to that, but I think if we
think about it then, it becomes obvious that there's some
potentially serious problems with that.

The experience that we have in medicine is not
particularly reassuring. Mark mentioned medical errors
that were described in the Institute of Medicine report a
couple years ago and have been the focus of a great deal of attention. That's certainly not very reassuring in terms of not so much necessarily quality issues but more price issues. There's a long history of antitrust violations going back to the 1930s on the parts of organized medicine. That, again, certainly gives one pause in this area. There have been numerous attempts to limit entry into profession, taken from restricting establishment of new medical schools, trying to restrict the entry of foreign-trained medical graduates and so on, that, again, perhaps are not extremely reassuring. Not to criticize physicians individually or even as a whole, but there certainly are these activities that have taken place.

So, let me then suggest that self-regulation won't do the job alone. We're going to need market incentives that markets will complement self-regulation. If we look at any industry, there are always standards boards, there are regulatory bodies internal to the industry and they work in concert with markets, but will not work particularly well on their own.

So, my conclusion is that antitrust enforcement is a critical element of health policy. It preserves the functioning of markets on which we base our system and perhaps I don't need to say this, but I will, it's
relevant for all payers, not just for private payers, but for public payers as well, Medicare and Medicaid. In particular, if some of the ideas that Tom Scully was talking about earlier take place, I will think that will only increase the reliance of the Medicare system on markets.

Now, let me switch gears at this point and start talking about quality and competition and be a little more focused in this area and we should first ask why is this important? I always tell my Ph.D. students, when they're thinking about a problem, to ask at least two questions. Well, certainly, the first two questions. One is so what and the second one is who cares. And if you can't answer those in some affirmative positive way, then let's move on and find another problem.

So, so what? Quality can matter a lot. I don't think I need to elaborate on that for this audience. There's a lot of variation. In some situations, the consequences of the variation can matter a great deal. In some cases, it's life and death. But even if it's not life and death, there can be important functioning and quality of life that are at stake.

Who cares? Again, I think the answer to that is obvious. All of us care because all of us are potential patients or we have family and friends who are
potentially patients and, again, more broadly speaking, we're all members of this society. So, I think these are easy questions to answer.

What do we know? I want to divide my presentation about what we do know into two pieces. What do we know from economic theory and then what do we know in terms of empirical evidence on the impact of competition on quality and health care markets up to this point.

I'll first focus on the theory because, as Mark says, it may work in practice, but we want to know first if it works in theory. And then I want to focus on empirical evidence. And in both theory and evidence, I'm going to divide the world into two pieces where prices are fixed, what Mark called administered prices, and where prices are free or variable or firms set their prices.

So, let me turn to what we know from theory generally. First, a comment. We should ask the question, whether competition has to result in both lower prices and higher quality to be a good thing. I'm just reinforcing what Mark Pauly said a moment ago, and the answer is no. Some people may be willing to accept lower quality if the price is low enough and some people may be willing to pay more if the quality is high enough. So,
high prices and low quality are probably bad. Low prices and high quality are probably good. Other combinations can be good or bad. So, let's take that as a general point.

Let me now talk about what we know from economic theory when prices are fixed. In this kind of situation, and this is like the regulated airline world, which some of you may remember. Unbelievably, one of those models had competition not over pub lounges but over meals per flight, which takes some of you way back. Competition over non-price aspects of the product, which I'll call quality, but quality here could be a technical quality or clinical quality or some kind of amenities. Competition is going to lead to more quality in that kind of a world.

The level of quality will vary with the price. It could be too high, too low or just right, and the price will determine whether that's the case. So, again, here, what we're really talking about for the most part in health care is Medicare.

One other result from economic theory is that even if competition doesn't lead us to the right amount of quality, if it's too high or too low, monopoly is worse. It always results in insufficient quality. So, even if competition leads us to too low a level of
quality, monopoly will provide even less. So, monopoly is never a good thing in a world with fixed prices or administered prices. Theory is very clear on that.

Where prices are variable, where firms can choose both price and quality, theory is very unclear. The response of the economic theory here is definitely maybe and that's final. Anything can happen. A monopoly can under-produce quality, it can overproduce quality and similarly for competition.

Now, in specific models under specific conditions, you can get definite predictions about whether monopoly or competition is better and, indeed, with careful thinking, one could take some of those competitions to a real world situation and try and examine whether they hold. That may not be quite so easy, but in principle, it is feasible to do that if there are some models which give you results that intense competition does result in lower prices and higher quality and consumers are better off. But those are only general models. There are no general results that point in that direction.

So, economic theory here is not a general guide. What this then implies is this is an empirical question and, in particular, what happens could vary across markets because conditions could vary across...
markets, and that's important to keep in mind. One of the longstanding empirical observations in health care is there are very wide variations in amount and types of care and expenditures on care across geographic markets. In some sense, that's not particularly surprising because we do see conditions varying across markets and all of those could be good, all of those could be bad. More careful thinking is required on this.

Let me say one last thing about theory and then I want to move on to empirical evidence. I want to talk about monopsony here or buyer market power. What do we know from theory? There's no question that buyer market power, monopsony, is bad. If the other side of the market is competitive, introducing market power on the buyer's side is bad. It definitely reduces social welfare just like monopoly.

Now, those results are when price is the only factor. The quality is not variable, it's not free. We don't actually know from economic theory what would happen in markets where there's monopsony power and both price and quality or product diversity are choices of firms. We do not have results on that. But certainly it's true for price, that there's no question monopsony is bad.

What about countervailing power? Say if
there's monopsony on one side of the markets, suppose
that an insurer had market power as a buyer, increasing
the market power of sellers, like physicians -- and these
are proposals behind the Campbell Bill and Barr-Conyers,
for example -- that is very unlikely to improve matters.
The most likely outcome is it makes things worse and
you're just going to reduce consumer welfare further. It
may improve the well-being of sellers, but it will reduce
the well-being of society as a whole, under most
circumstances.

As I already said, we don't actually know
anything from theory about impacts on quality. We might
expect monopsony to make things worse, but so far as I
know, there are no results.

Let me now talk about empirical evidence.
There is a clear prediction from theory about what should
happen when prices are fixed, when they're not variable.
Theory does not have clean predictions about what will
happen when prices are variable and quality is variable
as well.

Let me first talk about evidence from studies
that look at Medicare, where prices are fixed, and then
I'll move on to studies that look at other insurers as
well, or services for other insurers.

Let me say a couple things about where the
evidence comes from. These are econometric, statistical studies using secondary data. There's not a lot of evidence at this point. It's not like there are only two or three studies. There are a number of studies, but there's not a large amount of evidence. The evidence that I'm aware of to this point entirely has to do with markets for hospital services. So, let me move on.

Evidence on fixed prices, the first study I'll mention is a study of Medicare enrollees with AMI and this, in my opinion, is the best, the most careful, the most rigorous study out there at this point in time. This study is the gold standard. There are a number of other studies, and I'll tell you about some of the results. But I think this is the best study that we have at this point in time.

The authors looked at all Medicare beneficiaries who did not live in rural areas, the AMI for four selected years, 1985 to 1994. They found that risk adjusted one year mortality, not just inpatient, but one year mortality was significantly higher in more concentrated markets. So, markets with fewer sellers or if the market share was concentrated in the hands of one or a small number of hospitals had worse outcomes in terms of risk adjusted one year mortality. And the numbers are actually pretty eye opening. Comparing
patients who were in the most concentrated markets to those in the least concentrated markets, those in the most concentrated markets faced expected mortalities of 1.46 percentage points higher than those in the least concentrated markets. That was an over 4 percent difference. They also found that Medicare costs were lower in more concentrated markets before '91, higher after 1991. So, before '91, they say, well, in less concentrated markets, you have higher quality and lower costs, so that's unambiguously welfare improving. That's their claim. After '91, it's not completely clear, it's somewhat more ambiguous. But the results on AMI mortality are very clear.

Now, of course, this doesn't tell us about all conditions. But in order to be precise, the study does have to be focused.

Let me tell you about some other results. There's a recent study that looked at Medicare enrollees with AMI and pneumonia. Actually, this study also looked at HMO enrollees, but I'll give you those results a little bit later. They only looked at Los Angeles County. They found that risk adjusted mortality was significantly lower in more concentrated parts of Los Angeles County. So, the opposite, that mortality is worse in less concentrated areas and better in more
concentrated areas.

Now, this is only Los Angeles County, so it's a little hard to know exactly what that means. It's not clear that there's really sort of significant variation in competition within Los Angeles County or not. But these are the results and they do run in the opposite direction from the study that I just told you.

Mark and Phil Held, a number of years ago, looked at dialysis facilities. One of the results which he didn't mention is they found fewer dialysis machines per patient provided in more concentrated markets. In other words, less concentrated markets, presumably more competitive, there were more dialysis machines per patient which means that's easier to get in and get scheduled, more convenient and presumably better service.

Literature on the medical arms race, which looked at data prior to the mid-1980s, found things like hospital costs, hospital inpatient length of stay, service offerings, excess capacity were higher in less concentrated markets. Again, presumably in those markets, more competitive. The notion there was some kind of an arms race going on between hospitals, that may be the case. I think that most analysts concluded that that was over by the early '90s, though as Paul mentioned, there may be some regeneration of those kind
of strategies at present.

Let me move to the evidence on variable prices, where prices are not fixed, and there are a few different studies here. One study looked at the effect of a number of hospitals in a market on hospital profits and on the quantity of hospital care consumed in the market. They looked at isolated markets in the United States in 1990.

So, some large, but usually 100,000 is the largest market because of the criteria of being isolated. And the finding is that quantity increases with the number of hospitals in the market; profits decrease. Why might that happen? This study didn't directly measure quality or price, but attempted to infer what might be occurring, and the notion is that, well, if you found that competition increased and consumption increased at the same time, then there must be more value for money. Either prices went down or quality went up, but there was something that happened that made people want to consume more, not less. So, that is evidence that competition leads to a welfare improvement.

There's a study that looked at hospital mergers in California in the early '90s. There were about 130 mergers they were able to examine. About half of those were mergers of independent hospitals. Half were hospitals that were members of systems and got absorbed.
They did not find any detectable impact on inpatient mortality for heart attacks or stroke patients that was inpatient mortality only. They did find some mergers increased readmission rates for heart attack patients, which is an acknowledged bad outcome, and early discharge of newborns.

Another study looked at New York State over most of the 1990s, looking at patients receiving angioplasty, PTCA and CABG bypass surgery. This study found the following, that risk adjusted mortality was lower as a result of a specific kind of hospital acquisition, an acquisition where the acquiring hospital already provided angioplasty or bypass and the target, the acquiree, did not. There were 28 such acquisitions.

In addition, I classified this under variable prices, but rate regulation in New York State went off the books in 1996. So, prior to the period here, prices are fixed; part of the period, prices are variable. The author of the study did not explicitly account for that.

Another study looked at all heart attack patients, AMI patients, and compared New Jersey against New York, looking at the period 1990 to 1996. Now, what's interesting about this study is that New Jersey got rid of rate regulation in 1992 and New York did not.
So, they contrast the change before '92 and after '92 and New Jersey did the change before and after '92 in New York. Rate regulation went off the books in New Jersey. After '92, it stayed on the books in New York. They found that for these AMI patients, that risk adjusted inpatient mortality increased in New Jersey after the end of rate regulation.

Another study, this is the Los Angeles study, looked at not just the Medicare beneficiaries, but also HMO enrollees, also with AMI and pneumonia. For HMO enrollees, they found that risk adjusted mortality was significantly lower -- less concentrated -- that slide reads wrong -- less concentrated parts of Los Angeles County. So, the reverse of what they found for Medicare beneficiaries. For Medicare beneficiaries, they found that concentration was good for them in the sense of lower risk adjusted mortality. Here, concentration is bad for HMO enrollees. It's a little bit hard to square these two results together, but that's what we have at this point.

One more study here looked at angioplasty patients using a sub-sample of California hospitals. There were about 400 California hospitals in 1995, a little less. They found that excess mortality was lower for angioplasty patients in less concentrated markets.
So, again, if we think that competition is more intense in less concentrated markets, this has a positive effect on health and lower mortality.

Let me say a little something about volume outcome. I haven't talked about this explicitly up to this point, but one thing with regard to hospitals that one might want to think about in the context specifically of, say, a merger is the following: There's a longstanding observation that there's been a positive relationship between volume and outcome for treatments of a number of different kinds. So, heart surgery is one example of that. And that's not too terribly surprising. That accords with a lot of popular wisdom.

If we think that there is such a positive relationship and it's real, then we might think that a merger could provide some benefits potentially, because if we have a merger and volume goes up in the post-merger, in the merged entity, then outcomes could improve and that would be a good thing.

Now, there have been many, many studies of this. These studies have not been able to establish a causal relationship. It's not hard to imagine why. You think about volume outcome, you think of chicken/egg. Is it that high volume is causing good outcomes or good outcomes are causing high volume? And the answer is
probably a little bit of both. Trying to think of some
third factor that affects, say, volume but not outcome,
is not so easy to come by.

There is a recent study that looked at
angioplasty in California, and this is not a perfect
study, but it is a study that, I think, does shed some
light on this. This study measured outcomes in hospital
mortality and also by whether the angioplasty patient
required an emergency bypass. That's a bad outcome if
that happens.

So, the finding was that all hospitals achieved
substantial improvements in outcomes over time. That
over time, hospitals learned. But that volume didn't
have all that much to do with it. So, annual volume of
hospitals did have an impact, but it was relatively
small, and cumulative volume at a hospital had no
detectable impact on outcomes.

So, I don't know if this is the final word, but
this study does cast some doubt on the notion that
there's this strong relationship between volume and
outcome, and in terms of thinking about, say, a merger,
one might want to rethink this.

So, let me summarize, what do we know? The
evidence that I told you about, the empirical evidence is
only for hospital markets. The empirical evidence is
mixed. The strongest evidence I think that we have thus far is that quality is higher in less concentrated markets, which is consistent with the notion that competition does improve quality. But I do want to emphasize that there are conflicting results across these studies. The gold standard study that I did state that is the best study, I think, that's been done so far, does have that result. There are studies that go other ways. I don't think those studies are as good if you did something like counted up the studies and said which had a result that outcomes are better in less concentrated markets, there would be more of those than studies that said it goes the other way, although I'm not suggesting that's a scientific method for evaluating evidence.

What don't we know? Well, not too surprisingly, there's a bunch of stuff that we don't know. We don't know how competition effects both quality and price. There have not been studies that have taken account of both of those simultaneously and I'm not faulting anyone because it's hard to do. There's not much that we know about non-mortality aspects of quality. We don't know much about other important markets here. The triumvirate of markets for hospital services, physician services and insurer services, there's
virtually no evidence on the relationship between competition -- empirical evidence -- relationship between competition and quality and physician service markets or insurance markets.

In conclusion, quality is an important aspect of performance in health care markets. It certainly should be considered in economic and antitrust analyses of competition. The antitrust presumption is that monopoly is bad and competition is good. The scientific evidence that we have at this point is not sufficient to reverse that presumption with regard to quality. As I said, if anything, my take on it is that the preponderance of evidence is that more competition promotes quality rather than the other way around.

But, certainly, there's not sufficient evidence to overturn that presumption. There is no question, however, that quality should be considered in assessing competitive impacts and I think that will be an important part of antitrust to come.

Thank you.

(Applause.)

MR. HYMAN: Just a couple of brief wrap-up comments. Please note for the record we started 10 minutes late and we're finishing five minutes late. So, we picked up five minutes that you can use when you go
Second, all of the slides that got shown today will be up on the FTC web site early next week. I'm not sure about the Department -- no, Leslie's telling me not on the Department of Justice website.

Professor Pauly referred to a compassionate conspiracy of right thinking providers. The compassionate conspiracy of right thinking enforcers, that's Leslie and myself, have decided that we're going to cancel Friday afternoon, the Little Rock session, and that is primarily because there are ice storms in Little Rock and we don't think anyone will be able to get here. The weather forecasts for Boston are more promising, so we're planning to continue Friday with Boston.

However, we are intending to schedule Little Rock at a later date. So, we won't have them juxtaposed morning and afternoon, but we will get the benefit of both.

Finally, I'd like to thank you all for coming and thank all the speakers for the wonderful presentations they gave and I think all the speakers should get a round of applause at this point.

(Applause.)

MR. HYMAN: And we will continue tomorrow morning at 9:30 in this room. Thank you again.
(Whereupon, at 4:35 p.m., the meeting was adjourned.)
CERTIFICATION OF REPORTER

MATTER NUMBER: P022106

CASE TITLE: HEALTH CARE AND COMPETITION LAW

DATE: FEBRUARY 26, 2003

I HEREBY CERTIFY that the transcript contained herein is a full and accurate transcript of the notes taken by me at the hearing on the above cause before the FEDERAL TRADE COMMISSION to the best of my knowledge and belief.

DATED: MARCH 5, 2003

_____________________________________________________
SONIA GONZALEZ

CERTIFICATION OF PROOFREADER

I HEREBY CERTIFY that I proofread the transcript for accuracy in spelling, hyphenation, punctuation and format.

_____________________________________________________
ELIZABETH M. FARRELL

For The Record, Inc.
Waldorf, Maryland
(301) 870-8025